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CHAPTER 1: INTRODUCTION
Heart disease is the leading cause of death in women in the United States. In
1998, there were 503,927 women who died from cardiovascular disease, as compared to
lung cancer which claimed 64, 475 lives, and breast cancer which claimed 41,737 lives
(American Heart Association, 2001). Thus, though there are understandable and
widespread fears of cancer, particularly breast cancer, heart disease is a much larger
public health problem. Furthermore, some statistics suggest that heart disease may be a
more deadly disease for women than men. For instance, 38 % of women who suffer a
heart attack die within a year. By comparison, only one quarter of the men who have
heart attacks die within the year. Within 6 years of a first documented heart attack, 35 %
of women will have a second heart attack, as compared to just 18 % of men having a
second heart attack, in the same time period. Clearly, strategies designed to prevent heart
disease, such as lifestyle physical activity interventions or improved diets, should
command greater attention from postmenopausal women and their health care providers.
Additionally, hormone replacement therapy (HRT) had been recommended for its
purported benefits to heart disease risk factors and endpoints (such as heart attack or
death) in postmenopausal women. However, recent publications from the American
Heart Association and the National Cholesterol Education Program no longer recommend
HRT use for prevention of heart disease (Expert Panel on Detection Evaluation and
Treatment of High Blood Cholesterol in Adults, 2001; Mosca et al., 2001). The new
recommendations now state that women who choose to initiate or continue HRT useshould do so for established non-coronary benefits such as increased bone density and
decrease in menopausal symptoms (Mosca et al., 2001). Therefore, in spite of the change
in recommendations regarding heart disease, it is likely that there will continue to be a
large number of women taking HRT for its perceived health benefits to bone and its
proven effects in reducing menopausal symptoms. Additionally, physician prescribing
practices and patient health behaviors change slowly, and it is likely that any decline in
HRT use because of the change in recommendations, will occur slowly.
Hormone Replacement Therapy, Heart Disease Risk, and C-reactive Protein
There are several reasons behind the recent change in the recommendations
regarding HRT use and heart disease. The strongest evidence against HRT use for
prevention of heart disease comes from the Heart and Estrogen Replacement Study
(HERS), a randomized controlled trial that found that women with heart disease, who
took HRT, did not decrease their risk of heart attack or death (Hulley et al., 1998). Other
randomized controlled trials have strengthened the HERS evidence by showing that HRT
use did not affect the progression of atherosclerosis in patients with coronary disease
(Angerer, Stork, Kothny, Schmitt, & von Schacky, 2001; Herrington et al., 2000).In
addition to the HERS trial, recent studies have determined that HRT use leads to
consistently increased circulating levels of C-reactive protein (CRP) (Cushman et al.,
1999; Ridker, Hennekens, Rifai, Buring, & Manson, 1999).
CRP is an acute phase protein, synthesized in the liver, whose circulating levels
increase dramatically in response to acute bacterial infections, viral infections, or other
inflammatory conditions (Tracy, 1998). Chronic yet modest elevations in CRP have3
emerged as an independent risk factor for coronary artery disease (CAD) in both men
(Koenig et al., 1999; Ridker, Cushman, Stampfer, Tracy, & Hennekens, 1997; Ridker,
Glynn, & Hennekens, 1998) and women (Ridker, Buring, Shih, Matias, & Hennekens,
1998). In addition, recent studies have reported a role of CRP in both the initiation of
atherosclerosis and the precipitation of an acute CAD event (Pasceri, Willerson, & Yeh,
2000; Torzewski et al., 2000; Yudkin, Stehouwer, Emeis, & Coppack, 1999). Thus, the
observation of experimental increases in serum CRP after oral HRT administration is
cause for concern (Cushman et al., 1999).
C-Reactive Protein, Physical Activity and Exercise.
Because of the well-defined HRT-related increase in serum CRP, it is important
to examine lifestyle changes, like increased physical activity, which may offset that
increase. Serum CRP levels have been shown to decrease in response to endurance
exercise training in young healthy men (Mattusch, Dufaux, Heine, Mertens, & Rost,
2000), and in middle-aged healthy men and women (Smith, Dykes, Douglas,
Krishnaswamy, & Berk, 1999).Additionally, lower serum CRP levels have been
reported in the more physically active elderly participants of the Macarthur study of
successful aging (Taaffe, Harris, Ferrucci, Rowe, & Seeman, 2000). Similarly,
investigators from the Cardiovascular Health Study have reported significantly lower
serum CRP levels in the group of elderly men and women with the highest physical
activity levels (Geffken et al., 2001). Taken together, the above findings (Geffken et al.,
2001; Mattusch et al., 2000; Smith etal., 1999; Taaffe et al., 2000) provide evidence to
hypothesize that regular physical activity may offset the HRT-re!ated increases in serumri
CRP (Cushman et al., 1999). However, previous exercise aid physical activity studies
(Geffken et al., 2001; Smith et al., 1999; Taaffe et al., 2000) have not examined the
potential confounding influence of differences in oral HRT status among its
postmenopausal female participants. Oral HRT use is an important factor to consider
when exploring the relationship between serum CRP and physical activity, as higher CRP
values have consistently been reported for women on HRT (Cushman et al., 1999; Ridker
et al., 1999). Therefore, while physical activity and exercise have been shown to
decrease markers of inflammation (Geffken et al., 2001; Smith et al., 1999), it is not
known whether regular physical activity can independently offset the HRT-related
increase in serum CRP in women with differing HRT status.
Statement of Purpose I
The aim of the first manuscript in this dissertation is to determine whether higher
levels of physical activity are associated with decreased serum CRP levels in 133
postmenopausal women aged 50-78 years, independently of oral HRT use and other
important confounding factors such as age, past smoking history, present alcohol
consumption, statin use, aspirin use and body fat (both total and regional).
Insulin Resistant CAD Risk Factors and Biological Variability
The American Heart Association no longer recommends that HRT use be initiated
for the sole purpose of primary CAD prevention in postmenopausal women (Mosca et al.,
2001). Therefore, it may be especially important to determine the effectiveness of
lifestyle physical activity interventions, for managing heart disease risk factors that5
become more prevalent as women age. Insulin resistant CAD risk factors such as high
fasting glucose, insulin, triglycerides, and serum CRP levels (Festa et al., 2000), low
high-density lipoprotein cholesterol (HDL-C) levels, high blood pressure and abdominal
obesity, may be particularly important to target in lifestyle interventions with women
because diabetes is a more powerful risk factor for heart disease in women than men
(Mosca et al., 1999). Yet, risk factors in the insulin resistant syndrome, particularly
glucose, insulin, serum CRP levels (Festa et al., 2000), and abdominal obesity, have been
understudied in lifestyle modification trials with women. Previous investigations with
women have more narrowly focused on serum lipid and blood pressure outcomes. In
addition, previous studies with postmenopausal women have reported ambiguous
findings in that diet and physical activity interventions reduced some but not all of the
CAD risk factors being studied (King, Haskell, Young, Oka, & Stefanick, 1995; Kuller,
Simkin-Silverman, Wing, Meilahn, & Ives, 2001). These ambiguous findings may be
explained by the biological actions of physical activity. Alternatively, the finding may be
explained by unassessed differences in biological variability between outcomes. Thus, a
better quantification of the biological variability of insulin resistant CAD risk factors in
postmenopausal women is needed. Quantification of biological variability would
improve the likelihood of detecting significant lifestyle treatment effects while
maintaining feasible subject recruitment and retention estimates. By identifying those
risk factors with the highest biological variability, specific CAD risk factors could be
selectively targeted for serial assessment, prior to future intervention trials.Statement of Purpose II
The purpose of the second study in this dissertation is to quantify the biological
variability of insulin resistant CAD risk factors in 8 postmenopausal women, measured
on two occasions, 7-12 days apart. By conducting a reliability study with different
subjects, but subjects from the same population as the first manuscript, the findings about
biological variability will be directly applicable to the first study.7
CHAPTER 2
ASSOCIATION BETWEEN PHYSICAL ACTIVITY AND SERUM C-REACTIVE
PROTEIN TN POSTMENOPAUSAL WOMEN
WITH AND WITHOUT HORMONE REPLACEMENT
Patricia J. Mantis, MS PT, Daniel P. Williams, Ph.D., Christine M. Snow PhD., and
Rosemary C. Wander Ph.D
Submitted to the Journal of Internal Medicine
Blackwell Science, Osney Mead, Oxford, UK
June 20018
Abstract
Objectives: To determine whether higher physical activity is associated with lower serum
C-reactive protein (CRP), independent of oral hormone replacement therapy (HRT) status
and body fatness, in 133 postmenopausal women.
Design: Cross-sectional exploratory design
Setting: University research laboratory setting
Subjects: 133 postmenopausal women, aged 50-73 years, with no evidence of coronary
artery disease or diabetes.
Main Outcome Measures: Serum CRP, physical activity as measured by Stanford 7-day
activity recall, body fat (both total and regional) as measured by dual energy x-ray
absorptiometry (DXA) and anthropometry (waist and hip circumference). Secondary
outcome measures were triglycerides, total cholesterol, high-density lipoprotein
cholesterol and low-density lipoprotein cholesterol.
Results: Higher physical activity energy expenditures were significantly associated with
lower serum CRP levels (r=-0.21, p=O.Ol9), independent of oral HRT use, age, smoking
behaviour, alcohol consumption, aspirin use, and statin use. However, in the complete
multivariate model, which included body fat, the association between higher physical
activity and lower serum CRP levels was abolished and older ages (p0.029), greater
trunk fat masses (p <0.001), and oral HRT use (p <0.001) were independently
associated with higher serum CRP levels. The complete multivariate model accounted
for 48% of the variance in serum CRP.
Conclusions: This study is the first to report that greater amounts of physical activity are
associated with lower serum CRP levels, independent of oral HRT use.Furthermore, thepresent study suggests that physical activity-related reductions in body fat may be an
effective way to diminish the pro-inflammatory effects of oral HRT in postmenopausal
women.10
Introduction
Recent studies have raised awareness of the importance of vascular inflammation
in the biology, morbidity, and mortality of coronary artery disease (CAD) (26, 30, 31,
39). Elevated serum C-reactive protein (CRP) is an important marker of vascular
inflammation (11), is recognized as a "conditional" risk factor for CAD (36), and
becomes more prevalent with advancing age (17). Despite its effectiveness for
preventing age-related changes in blood lipids (41), oral hormone replacement therapy
(HRT) does not prevent CAD events (16) and increases serum CRP in postmenopausal
women (5). However, there are unequivocal bone density benefits (25) (19) and probable
cognitive benefits (14) of oral HRT use. Thus, it maybe premature to avoid oral HRT
use based solely on the findings of increased serum CRP. Furthermore, it is not known
whether healthy lifestyle behaviours, such as regular physical activity, can partially offset
the }IRT-related increase in serum CRP.
Endurance exercise training has been reported to reduce serum CRP levels in
healthy young men (21) and in healthy middle-aged men and women (35). Moreover,
physically active elderly men and women have lower serum CRP levels than their less
active counterparts (12, 38). However, to our knowledge, no study has examined
whether the inverse association between physical activity and serum CRP is affected by
oral HRT use in postmenopausal women.
Besides oral HRT, body fat is another important factor to consider because greater
amounts of body fat are associated with higher serum ClIP levels (6, 8). The production
and secretion of the pro-inflammatory cytokine interleukin-6 (IL-6), from fat cells,
provides an endocrine stimulus for hepatic CRP production (15), that links obesity to11
chronic low-grade inflammation (42). One limitation of previous studies reporting an
inverse association between physical activity and serum CRP levels is the use of body
mass index (BMI) to assess body composition (12, 38). BMI may not accurately reflect
body fatness in older women with declining stature and bone mass (13). Therefore, in the
present study we used dual-energy x-ray absorptiometry (DXA) to assess total and
regional fatness, a method that accurately reconstructs total body mass from its bone
mineral, soft tissue lean and fat components (28).
Thus, while physical activity and exercise have been shown to reduce circulating
markers of vascular inflammation (12, 35), it is not known whether higher physical
activity is associated with lower serum CRP, independent of oral HRT use and body
fatness, in postmenopausal women. We hypothesized that higher physical activity would
be associated with lower serum CRP levels, regardless of oral HRT use. However, we
also hypothesized that any association between physical activity and serum CRP would
be dependent, in part, on the lower body fat of the more active women.
Methods
Participants:
A total of 423 women responded by telephone to newspaper advertisements and
articles seeking participants in a study of physical activity and CAD risk factors in
postmenopausal women. Two hundred eighty three women were excluded during
telephone screening because of the use of non-oral forms of hormone replacement
therapy or selective estrogen receptor modulators, or for the presence of thyroid
disorders, cardiovascular disease, diabetes or gout. Women were also excluded if they12
had experienced a menses in the past year, or if they had surgical menopause before the
age of 40 years. Lastly, participants were excluded if they were taking cortico steroids,
niacin or fibrate medications. Of the 140 eligible participants, three were excluded
because of missing data, and four were excluded because of acute illnesses or infections
at the time of the blood draw. Thus, the sample described herein consists of 133
postmenopausal women age 50-78 years with no evidence of CAD, diabetes, or
infectious illness.
Procedures:
Metabolic outcomes, derived from morning fasting blood draws, included
glucose, insulin, total cholesterol (TC), triglycerides (TG), high-density lipoprotein
cholesterol (HDL-C), low density lipoprotein cholesterol (LDL.-C) and C-reactive protein
(CRP). Venous blood samples were collected in plasma EDTA tubes for glucose and
insulin and in serum vacutainer tubes with gel clot activator for TC, TG, HDL-C, and
CRP. Serum total cholesterol (2) and triglycerides (22) were determined with enzymatic
techniques. After precipitation of the apolipoprotein B containing lipoproteins with
phosphotungstic acid and magnesium chloride (3), serum HDL-C was determined
enzymatically (2). Low-density lipoprotein cholesterol (LDL-C) was calculated using the
Friedwald equation (9). A colorimetric glucose oxidase method (40) was used to assess
plasma glucose, and a human insulin-specific radioimmunoassay (Linco Research, St.
Charles, MO) was used to assess fasting plasma insulin levels. Our measurement errors,
expressed as coefficients of variation (SD/Mean x 100) were, 2.4% for TC, 4.4% for
HDL-C, 4.5% for TG, and 6.4% for glucose. For insulin, the coefficient of variation13
ranged from 3.0% for the high plasma insulin control to 7.1% for the low plasma insulin
control.
Serum CRP levels were measured in duplicate with a highly sensitive enzyme-
linked immunosorbent assay (Diagnostic Systems Laboratories, TX). The serum dilution
protocol recommended by the manufacturer is 1:500 and is primarily set to detect acute
infection/inflammation in a clinical laboratory setting. As such it is not designed to
record modest, chronic subclinical inflammation. Therefore, the dilution protocol was
modified and serum samples were initially diluted 1:50 with assay buffer, which resulted
in detectable serum CRP values of 0.5 to 25 mg/i. After initial analyses, samples that fell
above the detectable range were reanalyzed with a serum dilution of 1:500 (detectable
range 5-250 mg/i), and samples that fell below the detectable range were reanalyzed with
a serum dilution of 1:5 (detectable range 0.05-2.5 mg/I). Our interassay coefficient of
variation was 5.2 % for low-level serum CRP control that ranged from 1.2 to 1.4 mg/I,
and 6.6% for high-level serum CRP control that ranged from 11.4 to 13.3 mg/i.
On the same day as the blood draws, body weight, height, anthropometric body
composition measures (waist and hip circumference) and total and regional body
composition were measured. Body weight was recorded with a Detecto balance beam
scale (Metro Equipment Corp., Sunnydale, CA), and height was measured with a wall-
mounted stadiometer.Waist and hip circumference were measured with a steel tape
measure, according to the Anthropometric Standardization Manual (20). Total and
regional body composition were measured using a Flologic QDR 1000/W DXA scanner,
with analytical software version 5.71. Body composition is reported as percent body fat
as well as trunk fat mass using the anatomical region of interest that excludes the head,14
the arms, and the legs.Participants also completed a medical questionnaire that
addressed medication use, smoking history (divided into 'never' or 'ever' smokers),
alcohol consumption, and standard medical history questions.
Estimates of physical activity caloric expenditure were assessed by a trained
interviewer using the Stanford 7-day physical activity recall (34). However, we deviated
from the standard protocol for estimating physical activity energy expenditure in two
important ways. First, to be consistent with current physical activity recommendations
for accumulating moderate or higher intensity activities (27), we did not include a
calculated estimate of unreported "low-intensity" physical activity. Second, to further
improve accuracy, caloric expenditures were calculated with the recommended metabolic
equivalents for each specific activity from the Ainsworth Compendium of Physical
Activities, rather than rely on "blanket" metabolic equivalents that do not account for the
specific type of activity reported (1). Physical activity is reported as kilocalories of
energy expended per kilogram of body weight per week.
Data Analysis:
SPSS Version 9.0 was utilized for all data analysis. Descriptive statistics for three
HRT groups (no HRT, estrogen plus progestin, unopposed estrogen) were used to
determine the normality of metabolic and behavioral data. Because the distribution of the
values for C-reactive protein was skewed, log-transformed CRP values were used for all
parametric statistical hypothesis testing. However, the untransformed median CRP
values are presented for clinical interpretation.Analysis of variance (ANOVA) was used
to determine significant HRT-related differences in serum CRP, physical activity, body15
composition, and other metabolic CAD risk factors. In addition, chi square analysis was
used to determine whether there were HRT-related differences in the proportion of
women who were former smokers, statin users, present alcohol consumers or aspirin
users.
To determine the associations among physical activity, serum CRP, body fatness,
and selected CAD risk factors, partial correlations were used with statistical adjustments
for oral HRT use, age, smoking, alcohol consumption, statin use, and aspirin use. Older
ages (17) and cigarette smoking (4) are associated with higher serum CRP levels,
whereas aspirin use (29), statin use (32), and moderate alcohol consumption (18) are
associated with lower serum CRP levels. Multiple linear regression analysis was then
used to determine whether the association between physical activity and serum CRP was
independent of body fat and all of the above potential confounding factors.
Subsequently, an analysis of covariance (ANCOVA) was used to determine whether
there were significant interactive differences in serum CRP in groups of women stratified
by oral HRT use and physical activity tertile, with age, smoking status, alcohol
consumption, statin use and aspirin use used as covariates. A similar ANCOVA was
used to determine whether there were interactive differences in serum CRP in groups of
women stratified by oral HRT use and abdominal obesity, defined by critical waist
circumference measurements (>88 cm and88cm) (24).
Results
There were50women (38%) who were not taking any form of HRT. Fifty-one
women (3 8%) were using oral conjugated estrogens plus progestin, and the remaining 3216
women(24%)were taking oral unopposed conjugated estrogens. Table2.1presents
participant characteristics by oral HRT use. Median (interquartile range) serum CRP
values in mg/i were as follows: 1.6(0.7-2.8)for the women not taking HRT,5.8 (2.1-8.4)
for the women taking combined estrogen and progestin, and 9.1(5.2 -21.1)for the
women taking unopposed estrogen.Thus, the median serum CRP levels for women
taking oral HRT with or without oral progestins, were3.5to5.5times greater than the
median serum CRP levels of the women not taking HRT. The serum CRP values in the
Table 2.1 Descriptive Characteristics of 133 Postmenopausal Women by Oral HRT use*
No HRT Estrogen Plus ProgestinUnopposed Estrogen
n=50 n=51 n=32 P-value
Age (yrs) 62.4 (7.8) 61.4(6.7) 62.9(6.6) 0.593
Weight(kg) 66.1 (13.0) 67.2(12.0) 71.3 (14.2) 0.194
Waist Circumference (cm) 80.5 (13.2) 79.9 (9.8) 83.3 (12.7) 0.324
Waist-to-Hip Ratio 0.78 (0.07) 0.78 (0.06) 0.78 (0.08) 0.835
Body imss index(kgIn-12) 25.1 (5.1) 25.3 (4.3) 27.0 (4.8) 0.171
DXA Total Body Fat (%) 1 30.6(6.6) 31.3 (6.5) 34.3 (6.3) 0.036
DXA Trunk Fat Mass (kg) 8.6 (5.3) 9.0(4.2) 11.2(5.3) 0.048
Insulin (pmoVL) 80.7 (38.8) 78.0 (26.9) 82.0(36.2) 0.856
Glucose (mmol/L) 4.9 (0.5) 4.8 (0.5) 4.9(0.6) 0.348
Total cholesterol (mnDVL) 5.5 (0.8) 5.4(0.8) 5.6(0.9) 0.401
Triglycerides (ninol/L) 1.4(0.9) 1.6 (0.8) 2.0 (1.1) 0.011
HDL-C(ninol/L)§ 1.6(0.3) 1.7(0.4) 1.9(0.5) <:0.001
LDL-C(mrmlfL)t 3.3(0.8) 2.9(0.8) 2.8(0.8) 0.009
Physical Activity (kcal/kg/week) 51.5 (39.9) 47.1 (31.7) 41.3(33.6) 0.449
LogCRP(mgfl) § 0.16 (0.51) 0.62(0.46) 0.97(0.47) <0.001
CRP>10mg/1(%) 6 16 50 <0.001
Past Smoker (%) 32 27 34 0.78 1
Present Alcohol Consumption (%) 64 76 75 0.330
Statin Use (%) 4 2 9 0.278
Aspirin User (%) 22 26 16 0.570
*Valuesexpressed as mean (SD) for continuous data, or percentages for categorical data.
Denotes significant difference between no HRT and Estrogen plus Progestin Groups
Denotes significant difference between no HRT and Unopposed Estrogen Groups
§Denotes significant difference between Estrogen Plus Progestin and Unopposed
Estrogen Groups17
women taking oral estrogen and progestins were significantly higher than the serum CRP
of the women taking no oral HRT and significantly lower than the serumCRPof the
women taking unopposed estrogen. Moderate or higher-intensity physical activity energy
expenditure, expressed relative to body weight (kcal/kg/week), was not different among
the HRT groups. As expected, lower serum LDL-C, higher serum HDL-C, and higher
serum TG were associated with oral HRT use (p0.011). There were no HRT-related
differences in fasting plasma glucose and insulin levels. However, body fat percentage
and trunk fat mass, as measured by DXA, were significantly lower in the women not
taking HRT, as compared to the women taking unopposed estrogen (p0.048). Lastly,
there were no HRT-related differences in smoking status, alcohol consumption, aspirin
use, and statin use.
Table 2.2 reports partial correlations among physical activity, serum CRP, and
selected metabolic outcomes of the insulin resistance metabolic syndrome, after
adjustment for potential confounding by oral HRT use, age, smoking behavior, alcohol
consumption, statin use and aspirin use. Higher serum CRP levels were associated with
higher fasting plasma glucose, higher fasting plasma insulin, higher fasting serum TG,
higher BMI, larger waist circumferences, and greater trunk fat masses. In addition,
higher weekly physical activity energy expenditures were associated with lower serum
CRP, lower fasting plasma insulin, lower BMI, smaller waist circumferences, and lesser
trunk fat masses.18
Table 2.2 - Partial Correlations of Physical Activity and Serum CRP with Selected
Metabolic Outcomes of the Insulin Resistance Metabolic Syndrome and Statistical
Adjustments for Oral HRT Use, Age, Smoking, Alcohol Consumption, Statin Use and
Aspirin Use.
Physical Log
Activity CRP
Log CRP 0.21* -
TG -0.15 0.37±
HDL-C 0.14 0.01
Glucose 0.05 0.19*
Insulin 0.18* 0.35
!
Body Mass Index -0.29t 0.61
Waist Circumference -0.25 0.60
Waist-to Hip Ratio -0.06 0.40
DXATrunkFat -0.31 0.63
1
<0.050
t <0.010
p <0.001
A multiple regression analysis showed that the independent association between
higher physical activity and lower serum CRP did not persist after adjusting for
individual differences in trunk fat mass (Table 2.3). In the complete multivariate model,
older ages (p=0.029), greater trunk fat masses (p < 0.00 1), and oral HRT use (p <0.001)
were independently associated with higher serum CRP levels and accounted for 48% of
the variance in serum CRP. Individually, DXA trunk fat mass explained the largest
share of the variance in serum CRP (3 5%).19
Table 2.3. Multiple Regression Analysis of Serum Log CRP from age, physical activity,
DXA trunk fat, oral HRT use, and selected health behaviors in 133 postmenopausal
women.
Variable b y-intercept P-value R2 SEE
Age 0.01189-1.037 0.029 0.482 0.426
Physical Activity -0.00023 0.835
DXA Trunk Fat Mass0.00007 <0.001
Oral HRT use 0.21800 <0.001
Aspirin Use -0.0 1848 0.837
Alcohol Consumption-0.02279 0.804
Smoking 0.05315 0.527
Statin Use -0.06933 0.700
SEE = standard error of the estimate
To illustrate the independent associations of oral HRT use and physical activity
with serum CRP, we plotted median serum CRP levels by physical activity tertile and
oral HRT use (Figure 2.1).There was no interaction (j=0.891) between oral HRT use
and physical activity. However, lower serum CRP levels were associated with higher
physical activity caloric expenditures at every type of oral HRT use (p0.020). By
contrast, higher serum CRP levels were associated with oral estrogen use at every tertile
of physical activity (p < 0.001).Serum
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Figure 2.1. Stereogram of Serum CRP by oral HRT use and Physical Activity Tertile.
Sample size of each group is shown on the bars.There were significant main effects of
physical activity (p=0.020) and oral HRT use (p<O.001) on serum CRP.
Finally, to demonstrate the independent associations of oral HRT use and
abdominal obesity with serum CRP, we plotted median serum CRP by oral HRT use and
abdominal obesity (Figure 2.2). There was no interaction between oral HRT use and
abdominal obesity (p=O.485). However, having a waist circumference above 88 cm was
associated with higher serum CRP levels for every type of oral HRT use (p <0.001).
Moreover, higher serum CRP levels were associated with oral estrogen use for women
with and without abdominal obesity (p <0.001).21
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Figure 2.2. Serum CRP by oral HRT use and abdominal obesity. Sample size of each
group is shown on the bars. There were significant main effects of abdominal obesity
(j<0.001) and oral HRT use (p<0.001) on serum CRP.
Discussion
In this investigation of 133 postmenopausal women, aged 50-78, we determined
that higher amounts of physical activity were associated with lower serum CRP levels
independent of oral HRT use, age, smoking, alcohol consumption, statin use and aspirin
use. Recently, investigators from the Cardiovascular Health Study (12) and the
MacArthur studies of successful aging (38) have similarly reported an association
between higher physical activity and lower serum CRP levels. However, the present
investigation is the first to demonstrate a significant association between higher levels of
physical activity and lower levels of serum CRP that is independent of oral HRT use.The present findings also extend earlier observations (12, 38) to a younger ('-40 years
younger), more active, and likely, a healthier sample of postmenopausal women.
However, as hypothesized, we found that the association between higher physical
activity and lower serum CRP and was not independent of lesser amounts of total and
truncal body fat. It is plausible that exercise-related improvements in body fat control
may be the most important mechanism whereby regular physical activity leads to reduced
serum CRP levels. By contrast, our findings (Figure 2) and the findings of others (6)
suggest that oral HRT use may increase serum CRP independent of the degree of body
fatness or the magnitude of overweight.
Therefore, if oral HRT is capable of increasing serum CRP, independent of body
fatness, and if regular physical activity can reduce serumCRP,dependent on the extent of
body fat control, then it is likely that physical activity and oral HRT affect serumCRP
levels through separate mechanisms. Interleukin-6 (IL-6) is an important pro-
inflammatory cytokine that may link obesity to vascular inflammation. IL-6 is expressed
and actively secreted by fat cells (23), and in turn, chronically high circulating IL-6 levels
may stimulate the hepatic overexpression ofCRP,thereby explaining the chronic, low-
grade, vascular inflammation accompanying obesity. Furthermore, oral HRT decreases
serum IL-6 levels (37), yet paradoxically increases serumCRPat every level of BMI (6).
Thus, it is likely that the first pass hepatic effect of oral HRT directly increases CRP
production in the liver through an exogenous pathway, bypassing the endogenous
endocrine stimulus from fat cell-derived IL-6. Future prospective trials should
determine whether exercise training is capable of reducing serum IL-6 and serumCRPin
the presence or absence of weight loss, to elucidate the exact mechanisms whereby23
regular physical activity may reduce vascular inflammation in postmenopausal women
undergoing and not undergoing oral HRT.
In this study we expressed physical activity in terms relative to the participant's
body weight. Thus, we purposely did not express physical activity in absolute terms
(kcal). When relative energy expenditure (in kcal/kg) is simply multiplied by body
weight (in kg) to determine absolute energy expenditure (in kcal), it assumes that the
basal metabolic rate is invariant and equal to 1 kcallkg of body weight/hour for every
person (1). However, for individuals in whom the basal metabolic rate deviates from the
assumed constant, the resulting estimates of absolute energy expenditure more closely
reflect body weight than the reported physical activity behaviour (1). In addition, the
present relative estimates of energy expenditure may be more useful because they
emphasize that physical activity goals should account for individual differences in body
weight.
We found strong associations between higher serumCRPlevels and components
of the insulin resistant metabolic syndrome, including higher fasting glucose, insulin, and
triglyceride levels, and greater abdominal fat masses. These findings are in agreement
with other reports (8, 10) and support the suggestion that chronic low-grade vascular
inflammation, as measured by serumCRP,is part of the insulin resistant metabolic
syndrome. However, the associations we found between serumCRPand two
components of the insulin resistance metabolic syndrome, body fat and HDL-C, were
somewhat unexpected. The correlations we found between serumCRPand body fatness
are consistently greater in magnitude (i.e. r0.60 vs. r0.40) than those reported
elsewhere (8, 10, 43). Although we used DXA to assess body fatness, the correlation of24
DXA-derived body fat or BMI with serum CRP were almost identical in magnitude (r
0.60, p < 0.00 1).Thus, there are several possible explanations for the relatively high
correlations observed herein. Previous investigations did not stratiQ their analysis by
gender(8, 10, 43),possibly masking higher correlations between serum CRP and body
fat in women than in men. Additionally, only one of the previous studies (10) measured
serum CRP with a similar assay protocol as the present study, which carefully reanalyzed
individual serum samples at the appropriate dilution to ensure that every sample fell
within the detectable range of the assay. Lastly, the relatively high correlations between
body fat and serum CRP in the present study may be due to the relative "healthiness" of
our sample. In studies where a greater proportion of participants with clinical or
subclinical CAD or diabetes are included, it becomes more likely that the serum CRP
may be elevated independent of the degree of obesity(33). Bycontrast, in non-diseased
individuals, obesity, rather than extensive vascular injury, may be the primary cause of
chronic modest elevations in serum CRP.
Contrary to other published reports(8, 10, 43),we found a non-significant
association between HDL-C and serum CRP. However, the simultaneous increases in
HDL-C (41)and serum CRP (5) that accompany oral HRT use likely negated the
expected inverse correlation between HDL-C and serum CRP. For instance, after
adjusting for age, smoking behaviour, alcohol consumption, statin use, and aspirin use,
we were able to detect a significant partial correlation between HDL-C arid serum CRP
(r= -0.346, p=.02)onlyin those women who were not taking oral HRT.
There are a number of study limitations to consider, including: 1) weakness of the
cross-sectional study design; 2) limited sample size of the women taking unopposed oral25
estrogen; and 3) lack of serum IL-6 measurement. Because of the cross-sectional design
of this study, no causal inferences can be derived from these findings. Prospective
exercise intervention trials are needed to determine the effectiveness of physical activity
in reducing serum CRP in postmenopausal women taking oral HRT. The smaller sample
size in the unopposed estrogen group is also a limitation. That group had significantly
higher body fat than the group without any oral HRT, which broadens the potential
explanations for the consistently higher serum CRP levels in the women using unopposed
oral estrogen.Lastly, measurement of IL-6 would have strengthened the mechanistic
insight underlying the present independent associations among physical activity, oral
HRT use, and serum CRP in postmenopausal women.
In summary, this study is the first to report that higher physical activity levels are
associated with lower serum CRP levels, independent of oral HRT use. Our finding that
the physical activity-serum CRP association was not independent of body fat does not
diminish the potential public health importance of regular physical activity.In addition,
the newly revised National Cholesterol Education Program guidelines encourage the use
of statins and discourage the use of oral HRT for lipid management and CAD risk
reduction in postmenopausal women (7). Thus, the present study suggests that physical
activity-related reductions in body fat may be an effective way to diminish the pro-
inflammatory effects of the oral HRT that will likely continue to be prescribed to reduce
bone loss and control menopausal symptoms. Therefore, with experimental
confirmation, the present findings may broaden the preventive health benefits of diet and
exercise programs aimed at reducing body fat or limiting age related body fat gains in
postmenopausal women taking oral HRT.26
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Abstract
Purpose: To quantify the biological variability of insulin resistant coronary artery
disease (CAD) risk factors in a sample of 8 postmenopausal women. Methods: Risk
factor outcomes were measured on two occasions, 7-12 days apart. Outcome measures
included serum total cholesterol, serum triglycerides (TG), serum high-density
lipoprotein cholesterol (HDL-C), serum glucose, plasma insulin, serum C-reactive protein
(CRP), waist and hip circumferences, abdominal sagittal diameter, systolic (SBP) and
diastolic blood pressure, and self-reported physical activity energy expenditure.
Biological variability was assessed using standard errors of measurement (SEM),
intraclass correlation coefficients, within-subjects coefficients of variation (CV), and
Bland-Altman plots. Results: With the exception of waist circumference, there were no
mean differences between measurements 1 and 2 (p0.160). High absolute biological
variability values (by SEM) were observed for serum TG (32.0 mg/dl), serum CRP (5.6
mg/I), SBP (4.0 mmHg), and physical activity (9.4 kcal/kg/week). High relative
biological variability (by within-subjects CV's27.3 %) was also observed for serum
TG, serum CRP, and physical activity. The Bland-Altman plots identified individual
outliers that accounted for much of the overall biological variability observed for serum
TG, serum CRP, plasma insulin, and SBP. Conclusions: Serial measurement of serum
CRP, serum TG, plasma insulin, SBP, and physical activity in a future lifestyle
modification trials in postmenopausal women may help in detecting their true responses
to the intervention.
Key Words: Serial assessment, serum C-reactive protein, serum lipids, blood pressure,
body fat, and physical activity.32
Introduction
The primary prevention of coronary artery disease (CAD) through lifestyle
modifications such as improved diets and more regular physical activity may be a cost
effective way to reduce the 650,000 first-time heart attacks occurring each year in the
United States (3). However, a physical activity trial designed to increase primary
prevention of CAD is not feasible due to the need for an unrealistically prolonged
intervention requiring a prohibitively large number of subjects (32). Nonetheless, it is
important to test the impact of physical activity interventions on modifiable CAD risk
factors as more feasible surrogates for primary CAD events. Such interventions may be
especially important for postmenopausal women. For instance, the most recent American
Heart Association Advisory recommends that hormone replacement therapy (HRT)
should not be initiated for the sole purpose of primary CAD prevention in
postmenopausal women (22).Thus, it may be especially important to determine the
effectiveness, efficacy and safety of non-pharmacological alternatives to HRT, like
physical activity, for managing CAD risk factors in postmenopausal women.
One of the most important health benefits of regular physical activity is its ability
to reduce insulin resistance (24). In fact, slowing or halting the progression of insulin
resistance to type 2 diabetes may be particularly important for women because diabetes is
a stronger risk factor for CAD in women than men (23). Today, diabetes (25) and CAD
(26) are increasingly recognized as inflammatory diseases, and serum C-reactive protein
levels (CRP) represent an important marker and amplifier of inflammation (33). Elevated
serum CRP levels have also been advanced as a new component of the insulin resistant
metabolic syndrome (10), which is a constellation of CAD risk factors that also includes33
high fasting glucose, insulin, and triglyceride levels, low high-density lipoprotein
cholesterol (HDL-C) levels, high blood pressure, and abdominal obesity. Thus, lifestyle
modification trials for older women should include a full spectrum of insulin resistant
CAD risk factors as biologically relevant outcomes that may be beneficially altered by
regular physical activity.
However, most physical activity interventions, to date, have focused somewhat
more narrowly on serum lipid and blood pressure outcomes (6, 15, 16). Moreover, the
lack of consideration of differences in biological variability among CAD risk factor
outcomes creates some ambiguity in interpreting the actual effects of physical activity.
For instance, one exercise lifestyle intervention increased plasma HDL-C but failed to
reduce plasma triglyceride or blood pressure levels in postmenopausal women (15).
Thus, the inconsistent treatment effects may reflect the specific biological actions of
physical activity, or alternatively, they may reflect unquantified differences in the
biological variability of the specific CAD risk factors assessed. Thus, a better
quantification of the biological variability of insulin resistant CAD risk factors in
postmenopausal women is needed. By identifying those risk factors with the highest
biological variability, specific CAD risk factors could be selectively targeted for serial
assessment, prior to future intervention trials, which in turn, may improve the likelihood
of detecting the true CAD risk factor response to lifestyle modification. Thus, the
purpose of this study is to quantify the biological variability of insulin resistant CAD risk
factors in 8 postmenopausal women, measured on two occasions, 7-12 days apart.34
Methods
Participants:
Nine postmenopausal women volunteered to participate in the present study.
Women were excluded during telephone screening if they used non-oral forms of
hormone replacement therapy or selective estrogen receptor modulators, or had thyroid
disorders, cardiovascular disease, diabetes or gout. Women were also excluded if they
had experienced a menses in the past year, or if they had surgical menopause before the
age of 40 years. Lastly, participants were excluded if they were taking corticosteroids,
niacin or fibrate medications. One subject was unable to have blood drawn the second
week. Therefore, the number of subjects with complete data for analysis was 8.
Procedures:
This study took place in the summer months and participants were measured on
two occasions, 7-12 days apart. To minimize inter-observer measurement error, on both
occasions, the same technicians were used to assess a given study outcome. Blood was
drawn from an antecubital vein, between 8-9 in the morning, following a 12-hour fast.
Venous blood samples were collected in plasma EDTA tubes for glucose and insulin and
in serum vacutainer tubes with gel clot activator for serum total cholesterol (TC),
triglycerides (TG), high-density lipoprotein cholesterol (HDL), and serum C-reactive
protein (CRP). Serum and plasma cryovials were then stored at 70C until all blood
collection was complete.
Every serum or plasma sample was assayed in duplicate, and the mean of each
duplicate was utilized in the data analysis. To eliminate inter-assay variability, every35
week 1 and week 2 serum or plasma analyte sample for every subject was analyzed
within the same assay. Analytical variability, which is a component of biological
variability, was determined by calculating the intra-assay coefficient of variation
(CV=[standard deviation/mean] x 100) using control serum or plasma samples with
known concentrations for all circulating CAD risk factors. Serum total cholesterol (2)
and triglycerides (21) were determined with enzymatic techniques. After precipitation of
the apolipoprotein B containing lipoproteins with phosphotungstic acid and magnesium
chloride (4), serum HDL-C was determined enzymatically (2). A colorimetric glucose
oxidase method (31) was used to assess plasma glucose, and a human insulin-specific
radioimmunoassay (Linco Research, St. Charles, MO) was used to assess fasting plasma
insulin levels. Serum CRP levels were measured with a highly sensitive enzyme-linked
immunosorbent assay (Diagnostic Systems Laboratories, TX). The serum dilution
protocol recommended by the manufacturer is 1:500 and is primarily set to detect acute
infection/inflammation in a clinical laboratory setting. As such it is not designed to
record modest, chronic subclinical inflammation. Therefore, the dilution protocol was
modified and serum samples were initially diluted 1:50 with assay buffer, which resulted
in detectable serum CRP values of 0.5 to 25 mg/l. After initial analyses, samples that fell
above the detectable range were reanalyzed with a serum dilution of 1:500 (detectable
range 5-250 mg/i), and samples that fell below the detectable range were reanalyzed with
a serum dilution of 1:5 (detectable range 0.05-2.5 mg/I).
On the same day as the blood draws, body weight, height, anthropometric body
composition measures (waist circumference, hip circumference, and abdominal sagittal
diameter), and blood pressure were measured. Body weight was recorded with a Detecto36
balance beam scale (Metro Equipment Corp., Sunnydale, CA), and height was measured
with a wall-mounted stadiometer.Waist and hip circumference were measured with a
steel tape measure, according to the Anthropometric Standardization Manual (18).
Abdominal sagittal diameter (ASD) was measured with a commercially available
abdominal caliper made by Holtain Ltd. (Dyfed, Wales, United Kingdom) (14). Body
circumferences and ASD's were measured in rotational order, and the mean of three
measurements that agreed within 1cm or less was used in the data analysis. Systolic and
diastolic blood pressures were measured by auscultation with the subject seated and
resting quietly for five minutes prior to cuff inflation. Blood pressure cuff size was
determined by right arm circumference measurements, and the mean of three blood
pressure measurements, one minute apart, was used in the data analysis.
Estimates of physical activity caloric expenditure were assessed, on both
occasions, by the same trained interviewer using the Stanford 7-day physical activity
recall (28). However, we deviated from the standard protocol for estimating physical
activity energy expenditure in two important ways. First, to be consistent with national
physical activity recommendations for accumulating moderate or higher intensity
activities (24), we did not include a calculated estimate of unreported "low-intensity"
physical activity. Second, in an attempt to improve accuracy, caloric expenditures were
calculated with the recommended metabolic equivalents for each specific activity from
the Ainswortb Compendium of Physical Activities, rather than rely on "blanket"
metabolic equivalents that do not account for the specific type of activity reported (1).
The same technician who interviewed the participants also converted the reported37
physical activities to metabolic equivalents. Physical activity is reportedas kilocalories
per kilogram of body weight per week.
Statistical Analysis:
A paired t-test was used to determine if there was a significant difference between
the measurements at week 1 and week 2. A repeated measures analysis of variancewas
used to quantify the within subjects variability, the between subjects variability, the
intraclass correlation, the effect size, and the statistical power. The within and between
subjects variabilities were expressed as a coefficient of variation (CV).Because the
distribution of serum CRP values was positively skewed, the denominator of CVs
calculated for serum CRP was the median rather than the mean value.
In addition to the within subjects CV, which was used as a relative expression of
biological variability, the standard error of measurement (SEM) was calculated (18) and
used as an absolute expression of biological variability. Thus, the percentage scale of the
within subjects CV facilitates a relative comparison of biological variability across CAD
risk factors, whereas the SEM quantifies the absolute biological variability within the
measurement units of each specific CAD risk factor. To further interpret the present use
of the SEM, 95% of the values for a specific CAD risk factor will fall within ± 2 SEM
from the mean of the serial assessments. Lastly, to graphically illustrate the statistical
agreement between serial measurements and to identify the presence of individual
outliers, Bland-Altman plots (7) were drawn for the circulating CAD risk factors, systolic
blood pressure, and for the self reported estimates of physical activity caloric
expenditure.38
Results
There were 8 postmenopausal women with complete data, who ranged in age
from 61-77 years (mean 68.1 ±5.3years). Two of the women were taking oral HRT in
the form of combined oral estrogen and progestin, and the remaining six women were not
taking any form of URT. All participants were non-smokers, and none were taking statin
drugs for cholesterol management or antibiotics for an infectious illness. In addition,
none of the women reported any acute infections, or any other acute or chronic
inflammatory illness during the course of the study. One of the women who was taking
combined HRT, also took aspirin regularly.
The descriptive statistics for both measurements, the test for differences between
measurements, the effect size, the observed power, the intraclass correlation coefficient,
and the standard error of measurement (S EM) are reported in Table 3.1. With the
exception of waist circumference, there were no significant mean differences between the
measurements at week 1 and week 2. Even though the same technician assessed waist
circumferences on both occasions, there was, on average, a 2 cm increase in waist
circumference at week 2 (p=0.012), which was not corroborated by any significant
changes in mean body weight or ASDs (p>O.222). Despite the limited sample size of
eight subjects with complete data, the small effect sizes suggest that a larger sample may
not have altered the general trend towards non-significant week-to-week changes in CAD
risk factors, body composition, and physical activity. For instance, with the exception of
waist circumference and systolic blood pressure, the effect sizes are0.18, which is
below the conventional threshold of 0.20 for a small effect size (9).Table 3.1. Descriptive statistics, power statistics, standard errors of measurement, and
intraclass correlation coefficients for circulating CAD risk factors, body composition,
blood pressure, and physical activity.
Ivitit 1Iviumit2 PFikt Si Pc SEMiCC
iUitJ(nkI) 2325(44.4) 235.3(402) 0.6) 0.03 6.6 12.1 0.95
Tik(n/d1) 130.9(72.2) 119.9(37.6) 0.5) 0.03 8.9320 0.90
H17C(irgfcll) 64.9(11.1) 67.6(11.8) 0258 0.18 18.7 4.6 0.92
Uux(ng/d1) 88.5(9.3) 90.5(11.0) 0.343 0.13 143 4.1 0.92
liulinØtYni) 9.9(27) 10.4(3.6) 0.616 0.04 7.4 1.6 0.85
C.itiseFtdn(ng'1) 3.5(1.5-8.3) 2.5(1.3-5.6) 0.338 0.13 14.5 5.6 0.34
V1iist thnn1n(ar) &).3 (8.8) 820(92) 0.010 0.64 85.0 1.6 0.99
Hpaiuni(an) 104.6(61) 103.8(5.7) 0.164 0.16 25.7 1.6 0.97
A4hhlimligt1a1 UantQ (a 19.8 (26) 19.8(27) 0.W3 0.02 65 0.3 0.99
ByVg1itQg) .4(7.5) 0(7.6) 0232 021 21.4 0.5 0.99
&dic1cx1F1sue(imfJ 128.3(18.6) 131.1 (15.9) 0.1W 0.26 27.6 4.0 0.98
UatcAic1xx1ue(nniJ 76.8(11.9) 78.0(92) 0.413 0.10 11.8 2.8 0.98
Ica1/1) 344(26.1) 37.6(28.7) 0536 0.03 8.7 9.4 0.93
Tin(niii) 8775(285.3) 934.6(3242) 0.471 0.08 102 146.1 0.86
Power is expressed as a percentage.
ICC - intraclass correlation coefficient.
SEM standard error of measurement, expressed in the units of each individual variable.
Time = time since last bout of moderate physical activity
The relatively large standard errors of measurement (SEM) for serum
triglycerides (32.0 mg/dl), serum CRP (5.6 mg/i), systolic blood pressure (4.0 mmllg),
and physical activity (9.4 kcal/kg/week) suggest that intervention-related changes in these
CAD risk factors would be difficult to detect in the absence of serial measurement. The
intraclass correlation coefficients (ICC) represent common variance between the two
measurements. The ICCs, except for serum CRP, ranged from r0.85 to r=0.99,
indicating reasonably good reliability between week 1 and week 2 measurements.Onesubject heavily influenced the low ICC of serum CRP. Thus, the ICC increased from
R=0.34 to R=0.97 with the exclusion of the one subject with a large 22 mg/i drop in
serum CRP from one week to the next.
In addition to the absolute measurement errors (in the form of SEMs), the relative
errors (in the form of CVs) were partitioned into their intraassay, within subjects, and
between subjects components (Table 3.2). The within subjects CVs reflect biological
Table 3.2. Intraassay, within subjects, and between subjects coefficients of variation for
circulating CAD risk factors, body composition, blood pressure, and physical activity.
CV(Tnassay) WithinSubjects) CVeSubjects)
Tca1 thlesterol (ng/dIJ 2.4 5.5 25.0
Triglycodcs (n'dI) 4.5 27.3 59.2
HrC(n/df) 4.4 7.4 23.5
GIuce(n'dl) 6.4 4.9 15.4
InsulinØ.tU/n-1) 3.0-7.1 17.2 41.5
C-rictie Prctein (n/1)
Waist circuni ère (cm)
flip Circtiniferene (cm)
Alxhriml Sagittal Diantta (cm)
Body Weight (kg)
Systolic Blood Pressure (nmllg)
Diastolic Blood Pressure (rml{g)
I1ical Activity OccaI/kWk)
6.4 239.8 254.8
2.1 15.6
1.7 7.8
1.9 18.9
0.9 16.1
3.3 18.7
3.9 19.1
27.9 104.3
CV Coefficient of variation(standard deviationlmean) x 100. Expressed as a
percentage.
CV (Intraas say) = analytical variability
CV (Within Subjects) = biological variability
variabilityrelativeto the appropriate mean or median value. Thus, the large relative
biological variability in serum triglycerides, serum CRP, and physical activity, whièh41
were all27.3%, further emphasizes the potential importance of serial measurement of
these CAD risk factors. The between subjects CVs ranged from 7.8 % for hip
circumference, to 254.8 % for serum CRP. For each variable, the between subjects
variability was2.2to 9.9 times greater than the corresponding within subjects variability.
Thus, despite the small sample of 8 postmenopausal women, there is a wide range of
individual differences in CAD risk factors and body composition, which supports the
generalizability of the findings.
The Bland-Altman plots illustrate the agreement between serial measurements for
the circulating CAD risk factors, systolic blood pressure (SBP), and physical activity
(Figures 3.1 and 3.2).Outliers are defined by Bland-Altman as difference scores that are
greater than 2 standard deviations above or below the mean difference. Thus, the
variables serum CRP, plasma insulin, serum triglycerides, and SBP all have one
individual outlier.For physical activity, there were no individual outliers. However,
the difference scores were widely dispersed around the mean difference, which suggests
that serial measurement of self-reported physical activity may provide a more stable
estimate of physical activity behavior. The Bland-Altman plots reinforce the earlier
recommendation that serial measures may be important for serum CRP, serum
triglycerides, plasma insulin, SBP, and physical activity, as they would help in
identifying individual outliers or in averaging repeated measurements to achieve more
stable baseline data prior to an intervention.e
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Figure 3.1. Bland Altman Plots for Outcomes without Outliers including Total
Cholesterol, HDL-C, Glucose and Physical Activity. The solid horizontal line indicates
the mean of the difference scores. The dashed horizontal lines indicate ± 2 standard
deviations from the mean difference score. The triangles represent women not on HRT
and the circles represent women taking combined HRT.150
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Figure 3.2. Bland Altman Plots for Outcomes with Outliers including Triglycerides,
Insulin, Serum CRP and Systolic Blood Pressure. The solid horizontal line indicates the
mean of the difference scores. The dashed horizontal lines indicate ± 2 standard
deviations from the mean difference score. The triangles represent women not on HRT
and the circles represent women taking combined I4RT.Piscussion
This study reports the biological variability of several insulin resistant CAD risk
factors, which are biologically relevant outcomes to include in lifestyle intervention trials
for women. Biological variability was primarily determined by the following criteria: a)
relative variability (within subjects CV); b) absolute variability (SEM); or c) the presence
of individual outliers in the Bland-Altman plots. The present study is unique and
potentially significant because of its assessment of an extensive complement of insulin
resistant CAD risk factors in a relatively understudied population of postmenopausal
women. Furthermore, the present assessment of biological variability included important
circulating markers of insulin resistance and vascular inflammation, which have been
mechanistically implicated in the etiology of diabetes (25) and CAD (26) and may be
reduced by more frequent participation in physical activity.
Serum CRP and serum triglycerides met all of the criteria for high biological
variability by demonstrating high absolute and relative variability, and by the presence of
individual outliers in the Bland-Altman plots. For serum CRP, the within subjects CV
was 239.8%. The one outlying subject, with a 22 mg/l drop in serum CRP, reported a
250 mg/day increase in supplemental vitamin C intake from one week to the next. It is
not entirely clear whether the subject'sreportedincrease in supplemental vitamin C
intake is the only explanation for her substantial drop in serum CRP. However, a recent
study reports that higher serum vitamin C levels are strongly correlated with lower serum
CRP levels (r=-O.74, P <0.0001) (17).If the outlier for serum CRP is excluded from the
analysis, the within subjects CV drops to 33.2 %. By comparison, previous studies have
reported within subjects CVs for serum CRP ranging from 42% to 63% (8, 19,27).However, the previous reports were comprised of mixed study samples that included
younger and male subjects (8, 27). Thus, the paucity of postmenopausal women in the
earlier reports (8, 19, 27) makes it difficult to compare the present estimate of biological
variability in serum CRP with the earlier reports.
Serum triglycerides have long been known to have high biological variability. In
fact, our within subjects CV of 27.3 % for serum TG was similar to another study of
women that reported a within subjects CV of 30% for serum TG that were also assessed
on two occasions (13). Despite the similarity in the reported estimates of biological
variability for serum TG, the prior study (13) included premenopausal women with lower
TG levels than the postmenopausal women herein, and it used a longer sampling interval
between blood draws (28 days vs. 7-12 days). The one outlying subject, with a 117
mg/dl drop in serum TG, was an oral HRT user. However, just prior to each of the two
blood draws, she reported no change in premarin intake (0.625 mg/day), cycrin intake
(2.5 mg/day), duration of fasting (14 to 14.5 hours), or length of time since the last acute
bout of exercise (23-24 hours). Moreover, our within assay CV for serum TG was 4.5%,
so excessive technical error is not a likely explanation for the 117 mg/dl drop in serum
TO. Thus, there is no basis for removing this apparent "outlier" from our estimate of
biological variability in serum TG. Furthermore, our within subjects CV for serum TG of
27.3% is comparable to a review of 26 reports of the biological variability for serum TG
in humans (30). For instance, a mean within subjects CV of 21% was reported for serum
TO across 26 reports with a wide range of subject numbers (N10 to 7055), blood
samples (N=2 to 19), and time intervals between first and last blood samples (N2 to 141
days) (30).Physical activity energy expenditure, as measured by a 7-day physical activity
recall, displayed both high relative and absolute variability. Our within subjects CV of
27.9 % for total physical activity falls midway between the reported within subjects CVs
of 7% for total activity and 52% for non-occupational (or recreational) activity in another
study of older women (20). However, we used a 7-day physical activity recall, whereas
the other study used a 24-hour physical activity recall (20). By comparison to the earlier
report (20), our assessment tool required a relatively longer recall, which may have
contributed to its greater variability. However, another report of the biological variability
in self-reported physical activity, which used a 7-day physical activity recall (5) in much
younger elementary school teachers reported that 14 days of assessment was required to
achieve an estimate of physical activity that is 80% reliable in women. By comparison,
we are reporting that the first of two consecutive 7-day recalls accounted for 86% of the
cormnon variance in physical activity reported in the second 7-day recall in older
postmenopausal women. Our findings do not, in any way, imply that physical activity
recall is more reliable in older as compared to younger women. Instead, the length of
time between the repeated physical activity recalls was considerably shorter (1 week) in
the present study as compared to the previous report of younger women (1 year).
Moreover, the individual differences in self-reported physical activity between the two
consecutively administered 7-day recalls herein ranged from 25 kcal/kg/week to +19
kcal/kg/week, which questions the usefulness of interpreting a squared reliability
coefficient of> 80% as an acceptable standard of precision between repeated
measurements. Therefore, correlational assessments of reliability between repeatedmeasurements may be misleading because they do not account for the magnitude of
individual differences observed (7).
Fasting plasma insulin displayed low absolute variability (SEM=1 .6 p.UIml) yet
moderate relative variability (within subjects CV17.2 %). The one outlying subject,
with a 6 tU/ml increase in plasma insulin, reported no medication or supplement use on
either visit. Just prior to each of the two blood draws, she also reported little to no
change in either the duration of fasting (13 to 14.5 hours) or the length of time since the
last acute bout of exercise (11.5 to 13 hours). Moreover, our within assay CV for control
plasma insulin in the range of our fasting values was only 3%, which is a relatively low
technical error, that is also similar to an earlier report (29). Thus, there is no basis for
removing this apparent "outlier" from our estimate of biological variability in fasting
plasma insulin. Furthermore, our within subjects CV for fasting plasma insulin of 17.2%
is slightly lower than an earlier report of a within subjects CV of 21% for fasting plasma
insulin (29).
Systolic blood pressure (SBP) demonstrated somewhat high absolute variability
(SEM = 4.0 mmHg), yet somewhat low relative variability (CV3.3%). We interpret
the reported SEM for SBP (4 mmHg) as "somewhat high" in light of future attempts to
detect relatively modest physical activity-related reductions in SBP in predominantly
normotensive women. The one outlying subject, with a 9 mm Hg decrease in SBP from
week 1 to week 2, reported taking a non-prescription antihistamine the night before the
second morning visit. She also reported a greater length of time since the last acute bout
of exercise at the second laboratory visit (23 vs. 16 hours). Neither the medication
change nor the greater time since the last acute exercise bout, is a plausible explanation50
for the 9 mmHg decrease in systolic blood pressure. Besides, our SEM of 4.0 mmHg for
SBP is similar to an earlier study that reported a SEM of 4.5 mmflg for SBP in older
adults with peripheral arterial disease (11).
Similar to earlier reports (18), our anthropometric estimates of regional body fat
demonstrated low biological variability (within subjects CV <2.1%). Because of their
low biological variability, a single anthropometric estimate of body fat may suffice, as
long as the same technician is used at every measurement session. However, the
systematic difference in waist circumference, observed from week 1 to week 2, is
troubling. The difference is likely explained by the lack of easy-to-identify soft tissue
landmarks for waist circumference. By contrast, we observed no systematic difference
between the week 1 and week 2 abdominal sagittal diameter measurements, which use
easier-to-identify bony landmarks. Thus, researchers may want to consider measuring
the abdominal sagittal diameter as a useful alternative or additional anthropometric
estimate of abdominal fat.
The findings from the present study may help to explain some of the inconsistent
effects previously attributed to lifestyle modification. One study, of group vs. home-
based exercise reported a significant 24-month increase in plasma HDL-C but no change
in either plasma TG or blood pressure in older men and postmenopausal women (15).
The comparatively higher biological variability of serum TG and SBP, relative to serum
ITDL-C, reported herein, suggests that the unassessed and unaccounted for biological
variability of plasma TG and blood pressure may have contributed to the null effects of
exercise reported for these CAD risk factor outcomes (15). Another study of group-based
exercise reported a significant 11-month decrease in serum total cholesterol but no51
change in serum TG, serum HDL-C, or SBP in postmenopausal women (6). The
comparatively higher biological variability of serum TG, relative to serum total
cholesterol, reported herein, suggests that the unassessed and unaccounted for biological
variability of plasma TG and SBP may have again contributed to the null effects of
exercise reported for serum TG and SBP (6). However, it is not entirely clear why
exercise-related increases in serum HDL-C, which had a low biological variability herein,
were detected in one study (15) but not the other (6). We suspect that the ability to detect
exercise-related increases in serum HDL-C in oniy one of the studies (15) may be
explained by its inclusion of older men in the data analysis or by its longer study duration
(24 vs. 11 months).
The main limitations of the present study include the small sample size and the
use of only two rather than multiple measurements for study outcomes. A larger sample
size may have improved the quality of the estimates of biological variability. However,
an earlier review suggests that larger samples sizes are not imperative for obtaining
similar estimates of biological variability, in well-defined samples of subjects (12).
However, our assessment of insulin resistant CAD risk factors on only two occasions is a
limitation because we can make no recommendation regarding the optimal number of
serial assessments needed to obtain a truly stable estimate of a given risk factor.
Moreover, three or more serial measurements would improve the confidence in isolating
an outlying value for a given subject. However, due to the need to contain both study
costs and subject burdens, researchers conducting future lifestyle interventions who
choose to use serial measurements may not be able to measure a given study outcome
more than twice either before or after delivering the intervention. Two measurements are52
certainly better than one, as the average of two serial measurements may provide a more
stable estimate of an individual's true value at a given point in time. Further, a
comparison of serial measurements may help to identify aberrant values caused by non-
compliance with the measurement protocol, unavoidable changes in health behaviors,
unexpected cases of acute illness, and inconsistent uses of medications and nutritional
supplements.
In conclusion, we report that serum triglycerides, plasma insulin, serum CRP,
SBP, and self-reported physical activity all exhibit higher biological variability than
serum total and HDL cholesterol, serum glucose, diastolic blood pressure, and body fat in
postmenopausal women. Thus, the serial assessment of serum triglycerides, plasma
insulin, serum CRP, SBP, and physical activity in a lifestyle modification trial may help
in detecting their true responses to an intervention.53
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CIIAPTER4: CONCLUSION
Heart disease is the leading cause of death for men and women in the United
States, with almost 40% of all deaths each year, attributable to cardiovascular disease
(American Heart Association, 2001).This rate amounted to almost 1 million deaths in
1998. Up until the last3-5years, hormone replacement therapy (HRT) for post-
menopausal women was recommended, in part, for its purported improvements in heart
disease risk factors and the decrease in the incidence of heart disease events and/or
deaths. Recently, however, the American Heart Association has published a statement
saying that they do not recommend HRT use for primary or secondary prevention of
cardiovascular disease in postmenopausal women (Mosca et al., 2001). The American
Heart Association further recommends that the decision to take, or initiate HRT, should
be based on established benefits of HRT, including improvements in bone density and
menopausal symptoms (Mosca et al., 2001). Thus, there are millions of women and
doctors who will continue to use and prescribe HRT for its benefits to bone density and
for the control of menopausal symptoms.
Nevertheless, HRT use consistently leads to elevated serum C-reactive protein
(CRP) levels, which are a marker of inflammation, and a strong predictor of heart disease
risk in men and women. Additionally, more and more evidence is suggesting that
increased levels of serum CRP have a significant role in the initiation and progression of
athersclerotic plaque formation.Thus, the increased levels of serum CRP that
accompany HRT use are troubling.Therefore, the aim of the first study was to
determine whether higher physical activity levels could offset adverse HRT-related57
increases in serum CRP, independent of HRT use. The study, using a cross-sectional
design with 133 postmenopausal women, found a significant inverse association
(r=-0.21, p=O.O1 8)between increased physical activity energy expenditure and decreased
circulating levels of serum CRP. That association was independent of oral HRT use, but
dependent on body fat. This suggests that the most important mechanism by which
increased levels of physical activity, lead to decreased levels of serum CRP, may be
through a decrease in body fat.
The second study used a repeated measures design to examine the biological
variability of physical activity energy expenditure, and the insulin resistant CAD risk
factors measured in study one. Eight postmenopausal women were measured on two
occasions,7-12days apart. Using several statistical procedures, including standard errors
of measurement (SEM), intraclass correlation coefficients (ICC), coefficients of
variation, and Bland-Altman plots, the results showed that serum triglycerides, serum
CRP, plasma insulin, systolic blood pressure, and physical activity energy expenditure
had higher biological variability than total cholesterol, high density lipoprotein
cholesterol, glucose, and all body composition measures.
The biological variability findings may enhance our interpretation of the results of
study one, and provide recommendations for future exercise intervention trials with
postmenopausal women. For instance, study one reported a significant but relatively low
inverse correlation between higher levels of physical activity energy expenditure and
lower levels of serum CRP. We know, from the second study, that the biological
variability of both physical activity and serum CRP is large. Thus, it is likely that the
strength of the association between serum CRP and physical activity is being58
underrepresented in the absence of serial measurement techniques. There are several
future lines of research that would help to determine more clearly the role of increased
physical activity levels in the reduction of serum CRP.
First, longitudinal physical activity intervention studies with postmenopausal
women are necessary to determine the mechanism by which physical activity may
decrease serum CRP. Longitudinal studies would allow testing of hypothesized
mechanisms for the decrease in serum CRP reported with increased physical activity,
including a decrease in body fat or decreased insulin resistance. Secondly, measurement
of interleukin-6 (IL-6), the primary mediator of the acute phase inflammatory response,
would improve our understanding of the complicated relationships between IL-6, CRP
and HRT in postmenopausal women. Intervention studies, measuring IL-6, in addition to
CRP, may be particularly important in the determination of the mechanism by which
increased physical activity decreases serum CRP. Lastly, future studies with
postmenopausal women measuring insulin resistant CAD risk factors, particularly, serum
triglycerides, serum CRP, plasma insulin, systolic blood pressure, and physical activity,
would benefit from the use of serial measurement techniques. Serial measurement of
those outcomes, in particular, may improve the likelihood of detecting the true CAD risk
factor response to lifestyle modification.
In sunmiary, the present studies suggest that increased physical activity levels
play an important, possibly underrepresented role in decreasing serum CRP in
postmenopausal women. For future intervention studies, the present findings provide a
strong basis for the hypothesis that increased physical activity levels may decrease or
maintain more normal serum CRP levels in postmenopausal women who take HRT.59
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APPENDICESAPPENDIX A LITERATURE REVIEW
Heart Disease
Heart disease is currently the number one killer of American men and women, as
it has been for all but one of the past 102 years (American Heart Association, 2001). The
National Health and Nutrition Examination Survey III (1988-94) (NHANES) reports that
one in five people in America have some form of cardiovascular disease, which may
include high blood pressure, coronary artery disease (CAD), stroke and congestive heart
failure (American Heart Association, 2001). In 1998, cardiovascular disease resulted in
the death of almost a million people in the United States, with over half of those deaths
occurring in women. Though there are slightly more overall cardiovascular disease
deaths in women than men (53% vs. 47%), women as a group continue to live longer
lives than men. Researchers have long believed that greater longevity in women was
associated with the cardio protective effect of estrogen, as prior to the age of menopause,
women have a lower prevalence of heart disease than men (American Heart Association,
2001). At the age range of 55-64, for the first time, the prevalence of heart disease is
almost equal in men and women. By age 75, cardiovascular disease is more prevalent in
women, with almost 80% of women having some form of cardiovascular disease, as
compared to 71% of males. The mortality statistics for cardiovascular disease are
staggering, yet risk of cardiovascular disease could be significantly decreased with
lifestyle changes like smoking cessation, improved diet, and increased physical activity.
In addition to lifestyle changes, cardiovascular disease risk in postmenopausal women70
has historically been reduced by hormone replacement therapy (HRT) following
menopause.
Hormone Replacement Therapy
Menopause is a natural hormonal process in women, occurring between the ages
of 45 and 55 years, and is characterized by a decline in ovarian estrogen production and
the cessation of menses (Rousseau, 1998). There are a number of adverse symptoms
associated with menopause, including hot flashes, sleep disturbances, and mood swings.
Additionally, there is a marked increase in the rate of bone density loss (Lorrain, Plouffe,
Ravnikar, Speroff, & Watts, 1994), and an increased risk of cardiovascular disease (Bush,
2000). Because of the adverse changes associated with decreased estrogen levels,
hormone replacement therapy (HRT) was introduced for postmenopausal women, starting
in the 1940's.
HRT with oral estrogens has a 60-year history, with the first oral estrogen,
premarin, approved by the Federal Drug Administration in 1942 (Rousseau, 1998).
Conjugated equine estrogens (CEE), primarily premarin, hold the greatest market share in
hormone replacement therapy (Rousseau, 1998). In the United States, about 25 % of
postmenopausal women who experience a natural menopause, take or have taken in the
past, oral estrogen and progestin therapy. Of those 25 % of women who have taken
HRT, 10 % are current HRT users (Brett & Chong, 2001).
The large number of women who take and then stop HRT is likely explained in
part by the increased risk of endometrial hyperplasia, a transitory stage between healthy
and cancerous cells, and endometrial cancer with an unopposed estrogen regime71
(Greenblatt & Stoddard, 1978). For women with an intact uterus, the standard
postmenopausal treatment has become CEE combined with progestins (Rousseau, 1998).
The addition of progestin to unopposed estrogen regime decreases the incidence of
endometrial hyperplasia from 15-30% to 4% (Lorrain et aL, 1994) and protects against
the risk of endometrial cancer (Rousseau, 1998).Furthermore, oral HRT use leads to an
increased risk of breast cancer, and women who are identified as having a higher risk for
breast cancer should not be prescribed oral HRT (Rousseau, 1998).
The primary benefits of traditional hormone replacement therapy include: 1)
relief from menopausal symptoms; 2) prevention or control of the loss of bone density
associated with menopause; and 3) improvements in cardiovascular disease risk factors
(Rousseau, 1998). It has also been suggested that oral 1-IRT use improves cognitive
function but findings are inconsistent (Grodstein Ct al., 2000; Yaffe, Sawaya, Lieberburg,
& Grady, 1998).
A Closer Look at the Benefits of Oral HRT Use
One of the most important and least controversial benefits of oral HRT use has
been the benefit to the maintenance of bone density and decrease in fracture rate. Several
observational studies and reviews have reported that oral HRT reduces the fracture rate in
postmenopausal women (Cauley et al., 1995; Naessen, Persson, Adami, Bergstrom, &
Bergkvist, 1990). However, because HRT users tend to be white, more educated, and
more affluent than those who do not use HRT (Brett & Chong, 2001; Shah, Harris,&
Cook, 2001), findings from observational studies have been weakened by the potential
for selection bias. For example, greater bone density in women who take HRT may be72
partiy explained by the higher levels of education and affluence of women who take
HRT. HRT users, as a group are more likely to have been exposed to education and
intervention programs or mineral supplementation, than those with less education or
financial means. However, randomized controlled trials, a design that theoretically
minimizes or abolishes selection bias, report conflicting results with respect to bone
density.
For instance, the PEPI trial, a randomized controlled trial that examined the effect
of three different HRT regimes on a number of health outcomes, found that
postmenopausal bone loss was prevented by oral HRT use (Writing Group for the PEPI
Trial, 1996). Yet, a recent meta-analysis found that the evidence is weak about the
efficacy of oral HRT use in the prevention of fractures (Torgerson & BeIl-Syer, 2001).
Moreover, evidence from the Heart and Estrogen/Progestin Replacement Study (HERS)
found no reduction in the incidence of fractures or in the rate of height loss in non-
osteoporotic women taking oral HRT for 4 years (Cauley et al., 2001). Subsequently, an
editorial from the investigators of the HERS trial questions how good the evidence is
about HRT use and fractures and does not recommend oral HRT use for the prevention of
bone loss and fractures (Grady & Cummings, 2001). Nonetheless, findings about the
effect of HRT on bone density are not consistent in randomized controlled trials and
questions remain to be answered. Additionally, there are few randomized trials
examining bone density and HRT use in women with and without osteoporosis (Cauley Ct
al., 2001).
By contrast to the bone benefits of oral HRT use, which have only recently been
questioned, the cardiovascular benefits have been challenged since the results of the73
HERS trial were published in 1998. The evidence about the positive effects of oral HRT
use on cardiovascular disease mortality and morbidity has primarily been derived from
observational studies (Grodstein et al., 1997; Sidney, Petitti, & Quesenberry, 1997). The
Heart and Estrogen/Progestin Replacement Study (HERS) trial of 2763 women with
known heart disease, determined that there was no difference in the number of cardiac
events and deaths between women treated with HRT and those treated with placebo
(Hulley et al., 1998).In subsequent analyses, the HERS trial actually found that the
number of CAD events was significantly increased in the first year of oral HRT
treatment, as compared to the placebo group. The HERS study findings were disturbing
because they refuted the commonly held belief that oral HRT use reduced the risk for
CAD (Grodstein et al., 1997; Sidney et al., 1997). However, other studies have
corroborated the findings from the HERS trial. For example, the recently completed
Estrogen Replacement and Atherosclerosis (ERA) study found that HRT had no benefit
on slowing the progression of coronary atherosclerosis (Herrington et al., 2000).
Another recent randomized controlled trial confirms the ERA findings (Angerer, Stork,
Kothny, Schmitt, & von Schacky, 2001). The findings from these secondary prevention
studies (Angerer et al., 2001; Herrington et al., 2000; Hulley et al., 1998) have prompted
the National Cholesterol Education Program (NCEP) and the American Heart
Association to recently recommend that oral HRT not be used for the purpose of CAD
riskreduction in postmenopausal women (Expert Panel on Detection Evaluation and
Treatment of High Blood Cholesterol in Adults, 2001; Mosca et al., 2001).
Even though the NCEP and the American Heart Association no longer
recommend the use of oral HRT for CAD risk reduction, there is no evidence to support74
or refute the benefit of oral HRT in the primary prevention of CAD. The Women's
Health Initiative (Women's Health Initiative Study Group, 1998) is a randomized clinical
trial designed to determine the effect of HRT on primary CAD events (i.e. in women with
no history of CAD). The WHI is slated to be completed by 2005 and will provide much
needed information about HRT and the primary prevention of CAD. In the interim, there
are reasons to believe that oral HRT use may have an important positive role in the
primary prevention of CAD. For instance, the Postmenopausal EstrogenlProgestin
Interventions (PEPI) trial (Writing Group for the PEPI Trial, 1995), a randomized
controlled trial that examined differences in CAD risk factors in women randomly
assigned to 3 different HRT regimes and placebo, has reported improvements in serum
lipids (i.e. increased high-density lipoprotein cholesterol and decreased low-density
lipoprotein cholesterol) and fibrinogen in women who take HRT. Higher HDL-C and
lower LDL-C have been associated with decreased risk of CAD. Alternatively,
researchers may hypothesize that oral HRT use has a similar null or detrimental effect in
primary prevention, as in secondary prevention (Hulley et al., 1998) because of HRT-
related increases in serum C-reactive protein (CRP) (Cushman, Legault et al., 1999;
Cushman, Meilahn et al., 1999). However, until the WHI and other primary prevention
studies are complete, the effect of the HRT-related increase in serum CRP is not known
for women without heart disease. Some have speculated that high levels of serum CRP
are most detrimental to women with known CAD because of the destabilizing effect that
increased inflammation may have on unstable arterial plaques.75
HRT and CRP
The PEPI trial (Writing Group for the PEPI Trial, 1995) reported that women
treated with oral HRT demonstrated an 85% increase in serum CRP levels over three
years (Cushman, Legault et al., 1999), as compared to the placebo group. Similarly, the
Women's Health Study, a trial of aspirin and Vitamin E in the primary prevention of
cancer and cardiovascular disease among apparently health women, reported that CRP
levels in women taking oral HRT were two times higher than women not taking HRT
(Ridker, Hennekens, Rifai, Buring, & Manson, 1999). An extension of the Women's
Health Study observations showed that cases (i.e. women who subsequently had a
myocardial infarction, stroke, coronary artery bypass graft or cardiovascular death) had
median CRP values that were twice that of controls (Ridker, Buring, Shih, Matias, &
Hennekens, 1998). Thus, it is well established that serum CRP levels are elevated in
women treated with oral HRT.
CRP is an acute phase protein, synthesized in the liver, whose circulating levels
increase dramatically in response to acute bacterial infections, viral infections, or other
inflammatory conditions (Tracy, 1998). Historically, the clinical focus has been on
detecting large elevations in CRP as a marker of acute infection and/or inflammation.
More recently, and with improvements in assay sensitivity, chronic yet modest elevations
in CRP have emerged as an independent risk factor for CAD in both men (Koenig et al.,
1999; Ridker, Cushman, Stampfer, Tracy, & Hennekens, 1997; Ridker, Glynn, &
Hennekens, 1998) and women (Ridker, Buring et al., 1998). In addition, recent studies
have reported a role of CRP in both the initiation of atherosclerosis and the precipitation
of an acute CAD event. For example, CRP may play an important role in the76
recruitment of monocytes to the arterial wall, an early event in atherogenesis (Torzewski
et al., 2000). Moreover, CRP has been found to induce adhesion molecule expression in
human endothelial cells, an action that could potentially advance an atherosclerotic lesion
(Pasceri, Willerson, & Yeh, 2000). Inflarmnation may also facilitate the transition of
stable athersclerotic plaques to unstable plaques that are more susceptible to rupture,
thereby precipitating acute coronary events (Yudkin, Stehouwer, Emeis, & Coppack,
1999). Thus, due to the important roles of elevated serum CRP and vascular
inflammation in atherogenesis, atherosclerotic plaque progression, and plaque
destabilization, the observation of experimental increases in serum CRP after oral HRT
administration is cause for concern (Cushman, Legault et al., 1999). However, the
mechanism by which HRT use leads to increased serum CRP is not clear (Folsom et al.,
2001).
The primary regulator and mediator of CRP synthesis in the liver is a cytokine
called interleukin-6 (IL-.6). Thus, the first obvious mechanism of the HRT-mediated
increase in serum CRP is an up regulation of production of IL-6. However, circulating
IL-6, which is released from leukocytes, fibroblast, endothelial cells and adipose tissue in
response to disturbances in homeostasis (Heinrich, Castell, & Andus, 1990), is decreased
in women who take HRT (Straub et al., 2000). Thus, the HRT-related increase in serum
CRP does not appear to be mediated by IL-6. It is more likely that increased hepatic CRP
synthesis with HRT use is the result of a direct hormonal effect on gene regulation (van
Baal et al., 1999). Nevertheless, the mechanism of the HRT-related increase in CRP is
unclear. However, it is clear that serum CRP levels are increased by HRT use (Cushman,
Legault et al., 1999; Cushman, Meilahn et al., 1999; Ridker, Hennekens et al., 1999) and77
therefore it is important to explore lifestyle behaviors that may help to offset that increase
in women who take HRT.
Lifestyle Behaviors to Offset HRT-related Increases in CRP
With research about the benefits and risks of oral HRT use ongoing, it is
important to determine whether lifestyle behaviors, such as regular physical activity, can
offset the HRT-related increase in serum CRP. Serum CRP levels have been shown to
decrease in response to endurance exercise training in young healthy men (Mattusch,
Dufaux, Heine, Mertens, & Rost, 2000), and in middle-aged healthy men and women
(Smith, Dykes, Douglas, Krishnaswamy, & Berk, 1999). Additionally, lower serum
CRP levels have been reported in the more physically active elderly participants of the
Macarthur study of successful aging (Taaffe, Harris, Ferrucci, Rowe, & Seeman, 2000).
Similarly, investigators from the Cardiovascular Health Study have reported significantly
lower serum CRP levels in the group of elderly men and women with the highest physical
activity levels (Geffken et al., 2001).
The mechanism by which physical activity may decrease serum CRP levels has
not been fully elucidated (Folsom et ál., 2001). However, there is a strong association
between serum CRP and abdominal obesity (Hak et al., 1999; Yudkin et al., 1999) and it
has been hypothesized that the lower body fat associated with increased physical activity
levels may explain the lower serum CRP levels in those who exercise (Geffken et al.,
2001). In addition, insulin sensitivity and variables in the insulin resistance metabolic
syndrome, particularly triglycerides, fasting glucose and fasting insulin, and abdominal
obesity, have strong associations with serum CRP (Festa et al., 2000).Studies have78
shown that increased participation in both vigorous and non-vigorous activity, leads to
improved insulin sensitivity (Mayer-Davis et al., 1998). Thus, the lower levels of serum
CRP reported with increased physical activity may be mediated through improved insulin
sensitivity. Taken together, the above findings (Geffken et al., 2001; Mattusch et al.,
2000; Smith et al., 1999; Taaffe et al., 2000) and the biological plausibility of the
proposed mechanisms of physical activity related reductions in serum CRP, provide
evidence to hypothesize that regular physical activity may offset the HRT-related
increases in serum CRP (Cushman, Legault et aL, 1999). However, previous exercise
and physical activity studies (Geffken et al., 2001; Smith et al., 1999; Taaffe et al., 2000)
have not examined the potential confounding influence of differences in oral HRT status
among its postmenopausal female participants. Oral HRT use is an important factor to
consider when exploring the relationship between serum CRP and physical activity, as
higher CRP values have consistently been reported for women on HRT (Cushman,
Legault et al., 1999; Ridker, Hennekens et al., 1999).
Other Confounding Influences to Consider When Examining the Association Between
Serum CRP and Physical Activity
It is important to control for the potential confounding influence of body fat when
examining the independent associations among HRT use, physical activity and serum
CRP. Greater amounts of body fat are strongly associated with higher serum CRP levels
in both men and women (Festa et al., 2000; Hak et al., 1999). Physical activity has been
shown to decrease total and regional body fat (Going, Williams, & Lohman, 1995).
Moreover, oral HRT administration may reduce abdominal fatness in postmenopausal79
women (Samaras, Hayward, Sullivan, Kelly, & Campbell, 1999). Thus, physical activity
and HRT use may independently prevent some of the age-related gain in body fatness,
thereby confounding an association among HRT use, physical activity and serum CRP.
To account for potential confounding, previous investigations examining the physical
activityserum CRP relationship in postmenopausal women have used body mass index
(BMI) to assess body composition (Geffken et al., 2001; Taaffe et al., 2000).
Unfortunately, BMI is more inaccurate for women than men and is especially inaccurate
for older adults with declining stature (Going et al., 1995). Therefore, we have used dual
x-ray absorbtiometry (DXA), which accurately reconstructs total body mass from its bone
mineral, soft tissue lean, and fat components. BMI cannot differentiate between fat and
fat-free tissues. In addition to oral HRT use and body fat, other potential confounding
factors include statin use (Ridker, Rifai, Pfeffer, Sacks, & Braunwald, 1999), aspirin use
(Ridker et al., 1997) and moderate alcohol consumption (Imhof et al., 2001), all of which
have been shown to decrease serum CRP. Increasing age (Hutchinson et al., 2000) and
current smoking (de Maat & Kiuft, 2001), are also confounding factors as both have been
reported to increase serum CRP.
Therefore, while physical activity and exercise have been shown to decrease
markers of inflammation (Geffken et al., 2001; Smith et al., 1999), it is not known
whether regular physical activity can independently offset the HRT-related increase in
serum CRP in women with differing HRT status. Thus, the specfIc aims of this
investigation are: 1) to determine whether physical activity is associated with serum CRP
in 133 postmenopausal women aged 50-78 years, and 2) to determine whether a
signticant physical activity serum CRP association, ffound, is independent from HRT80
status, age, past smoking history, present alcohol consumption, statin use, aspirin use
and body fat (both total and regional). We hypothesize that higher physical activity will
be associated with lower serum CRP levels, regardless of oral HRT use. However, we
also hypothesize that any physical activity serum CRP association will be dependent, in
part, on the lower body fat of the more active women.
Biological Variability of Insulin Resistant CAD Risk Factors
Lifestyle physical activity intervention trials with postmenopausal women have, in
the past, focused primarily on lipid and blood pressure outcomes. However, diabetes is a
more powerful risk factor for CAD in women than men. Thus lifestyle intervention trials
should increase the range of outcomes they examine, to include the full spectrum of
insulin resistant CAD risk factors. The insulin resistant CAD risk factors that link insulin
resistance to type II diabetes, include high fasting glucose, insulin, and triglyceride levels,
high serum CRP, low high-density lipoprotein cholesterol (HDL-C) levels, high blood
pressure, and abdominal obesity. However, to fully understand and interpret changes in
outcomes pre and post physical activity intervention or to interpret associations between
insulin resistant CAD outcomes and physical activity, it is essential to quantify the
analytical and biological variability of those outcomes, postmenopausal women.
Analytical variability is the variation due to measurement error and is often
expressed as a coefficient of variation (standard deviation/mean) as calculated from
laboratory measurements of control samples. For metabolic outcomes, analytical
variability may be reported as both intraassay and interassay coefficients of variation.
Researchers attempt to minimize analytical variation by using only experienced81
assessors, having the same assessors on all occasions, and having the same person
analyzing all the metabolic assays. With sound procedures and appropriate assays
available, analytical variability can be effectively minimized.
By contrast, the magnitude of biological variability, or the variation within
subjects, is more dependent on pre-analytical variables, individual factors, and the
characteristics of the analytes measured (Marcovina, Gaur, & Albers, 1994). Pre-
analytical factors that influence biological variability include diet, smoking, exercise, and
alcohol consumption (Cooper, Myers, Smith, & Schlant, 1992). With standardized
testing conditions, the effect of pre-analytical factors on biological variability is
minimized. Thus, individual factors and characteristics of the analyte determine the
biological variability of an outcome measure under standardized testing conditions.
In order to determine biological variability, more than one measurement of an
outcome is required. Measurement of an outcome, on two or more separate days pre and
post physical activity trial is uncommon. Nonetheless, if biological variability was
measured in physical activity trials, it could be separated from treatment effects, thereby
increasing the likelihood that a significant treatment effect will be found. Similarly, in a
cross-sectional study, measurement of outcomes on more than one day is rare. Thus, if
an outcome, such as CRP or physical activity, has high biological variability, correlations
between variables will be attenuated (Baranowski et al., 1999).
The primary outcomes of interest for this dissertation are serum CRP and physical
activity. The biological variability of serum CRP has been calculated previously for
healthy subjects and variability was large, ranging from 42% to 63% (Clark & Fraser,
1993; Macy, Hayes, & Tracy, 1997; Sakkinen et al., 1999). Measurement of physical82
activity has also been shown to have large biological variability and two recent studies
reported that 14-21 days of physical activity assessment are required in order to achieve a
measure that is 80% reliable (Baranowski et al., 1999; Matthewsetal., 2001). The
biological variability of serum CRP and physical activity, and other important insulin
resistant CAD risk factors have not been characterized for postmenopausal women.
Therefore the aimofthe second study in this dissertation is to determine the biological
variabilityofinsulin-resistant CAD riskfactors inpostmenopausal women. The findings
about biological variability will be directly applicable to the first study in this
dissertation, which examined the associations between serum CRP and physical activity.83
APPENDIX B: INFORMED CONSENT FORM
OREGON STATE UNIVERSITY ENDOCRINE AND METABOLISM
LABORATORY
A. Title of Research Project
Hormones, Physical Activity, and Coronary Heart Disease Risk Factors in
Postmenopausal Women.
B. Investigators
Daniel P. Williams, Ph.D. (principal investigator), Rosemary C. Wander, PhD. (co-
investigator), Christine M. Snow, Ph.D. (co-investigator), and Janet M. Shaw, PhD. (co-
investigator).
C. Purpose of Research Project
You are invited to participate in an investigation of hormones and physical activity as
possible determinants of abdominal fat and other risk factors for coronary heart disease
(CHD) in postmenopausal women. It is known that higher amounts of abdominal fat are
associated with an increased risk for diabetes and CHD and that physical activity reduces
the risk for diabetes and CHD, in part, by minimizing the amount of abdominal fat that
accumulates in women after menopause. However, we do not understand all of the
hormonal factors that contribute to abdominal fat accumulation or to the possible
reductions in abdominal fat and other CHD risk factors that may be achieved through
physical activity.
Some preliminary studies in premenopausal women suggest that higher levels of male sex
hormones (androgens) and a stress hormone (cortisol) may contribute to abdominalfat
accumulation in women. Thus, the purpose of the present study is two-fold. First, the
study will determine whether greater amounts of abdominal fat, higher blood pressure
levels, and unfavorable blood cholesterol levels are associated with elevated blood levels
of insulin (a risk factor for diabetes and CHD), elevated blood levels of androgen and
with an elevated urine level of cortisol in postmenopausal women. Second, the study will
determine the amount or "dose" ofphysical activity associated with a loweringofknown
risk factors for CHD, so that we may better advise older women about how much
physical activity they should do to reduce their risk for CHD.
We hope to better understand the hormonal factors which explain why women tend to
accumulate more body fat in the abdominal region, tend to have higher blood pressures,
and tend to have more unfavorable blood cholesterol levels after menopause. We also
hope to better understand the biological explanations for why physically active women
are at lower risk for CHD, so that we may better understand how to prevent the increased
riskfor diabetes and CHD and postmenopausal women.84
D. Procedures
I have received and oral and a written explanation of this study, and I understand that I
was selected to participate in this study because I am a healthy postmenopausal woman
with no prior or existing diagnoses of cardiovascular disease, diabetes, or gout. In
addition, I was selected because I do not take a corticosteroid (i.e. prednisone), thyroid,
or gout medications. Furthermore, I understand that a participant in this study the
following things will happen over the course of a 3-4 hour laboratory visit and a second
trip to the laboratory to return a 24-hour urine sample:
BLOOD AND URINE COLLECTIONS. On the day of the laboratory measurement
session, I will arrive at the testing site in the morning, without having consumed anything
but water for the previous 12 hours. No more than 25 ml (4-5 teaspoons) of blood will be
drawn from a forearm vein. After the blood draw, I will be given a labeled 2.5 liter
container with 10 g of boric acid (as a preservative) and instructed to collect a 24-hour
urine sample. I will be asked to collect the 24-hour urine sample during an ordinary
weekday from 8:00 AM to 8:00AM. I will also avoid smoking and alcohol intake during
the 24-hr collection period, and I will promptly return the capped urine container to the
laboratory personnel within the first few hours after completing the 24-hr urine
collection.
BODY MEASUREMENTS. I will wear light shorts and a short sleeve shirt that can be
easily moved for the accurate measurement of body weight, height, skinfold thicknesses,
and girth measurements. My body weight will be measured on a beam scale, and my
height will be measured with a wall mounted measuring stick. My total body and
abdominal body fat will be assessed by skinfold thickness, body girths, and by the dual
energy x-ray absorptiometry scan (DXA), which is also used to measure bone mineral
(see below). My skinfold thicknesses will be measured with a caliper on the upper arm,
on the upper back, on the side of the torso, on the abdomen, and on the thigh. My body
girths will be measured with a measuring tape at the upper arm, waist, abdomen, hip, and
thigh.
BLOOD PRESSURE AND HEART RHYTHMS. My blood pressure and heart rhythm
at rest will be assessed by a device that automatically measures and records blood
pressures and heart rhythms. After cleaning the skin with alcohol swabs, adhesive
surface electrodes will be applied to the chest. A blood pressure cuff will then be placed
on the upper arm, and electrical wires will be connected to a Quinton Model 410
automated blood pressure and heart rhythm monitor (Quinton Instrument Company,
Seattle, WA). The heart rhythms will be used to determine heart rates and to determine
whether there are any heart rhythm changes that frequently accompany high blood
pressure.
DXA SCAN. My DXA scan will be obtained using a Hoologic QR 10001W
absorptiometer. The scans require that I lie quietly on a table for 15-20 minutes. The
technique gives an accurate measure of total body and abdominal fat with a very low85
exposure to radiation. The radiation dose is considered safe to administer on several
occasions to postmenopausal women who may no longer become pregnant. The
calculated radiation exposure is much less than a standard 2-position chest x-ray. The
dose is approximately 1.5 millirads per scan, as compared to and average dose of0.5
millirads per day from normal environmental exposure. Therefore, risk from
participation in the present study is negligible. I further understand that I will experience
no physical discomfort from the DXA scan.
MEDICAL HISTORY AND PHYSICAL ACTIVITY. I will complete a medical history
questioimaire, and I will respond to questions posed during and interview with a member
of the laboratory staff about my physical activity over the past 7 days. I understand that
the medical history questionnaire is detailed and includes many questions about the
health history of myself and my family that may even seem burdensome and intrusive.
Previous studies have shown that women on hormone replacement therapy and physically
active women tend to be healthier, have fewer medical problems and complaints, see
their physicians more regularly, and report a family history of chronic diseases and
conditions less frequently than women who are not on hormone replacement therapy and
women who are not physically active. Thus, the purpose of the extensive medicalhistory
questionnaire is to determine whether the association of known risk factors for CHD with
hormone replacement therapy and physical activity are independent of other health
behaviors, medical conditions, and family histories for disease that may also be
associated with the known risk factors for CHD, hormone replacement therapy and
physical activity. Despite the scientific relevance of the extensive medical history
questionnaire, I understand that is I find any part or parts of the questionnaire to be overly
burdensome or intrusive, I am under no obligation to complete it, and that my decision
will in no way affect my participation in other parts of the study.
FORSEEABLE RISKS OR DISCOMFORTS. FORESEEABLE RISKS OR
DISCOMFORTS. I understand that I may experience some discomfort while my blood is
being drawn and that this procedure could result in a small amount of bleeding, bruising
and slight soreness at the site of the needle insertion. I have been informed that my blood
will be drawn by trained personnel who will apply a bandage to my arm to prevent
bleeding or bruising as a result of the blood draw.
I understand that the urine collection procedure may result in some inconvenience relate
to carrying the urine container and collecting all the urine produced over and entire 24-
hour period. I understand that I must keep that I must keep the urine container dry and
capped when not in use. I have also been informed to keep the urine container in a cool,
dry location that is relatively safe from disturbance by family members and pets.
I understand that the skinfold measurement thickness measurements may produce some
mild discomfort associated with pinching of the skin. I have been informed that skinfold
thicknesses will be measured by trained personnel who will minimize the risk of
discomfort by using a standardized measurement protocol which involves a minimal
amount of time that the skin is pinched.86
I understand that the blood pressure measurements may also result in some mild arm
discomfort associated with the inflation of the blood pressure cuff I have been informed
that the blood pressure measurements will be made by trained personnel who will
minimize the risk for discomfort by using standardized measurement protocol which
requires a measurement of upper arm girth to ensure that a properly sized blood pressure
cuff is used.
BENEFITS FROM RESEARCH. I understand that the measurements of body fat,
physical activity, insulin, blood pressure, and blood cholesterol, which will be sent to me,
may be important to me or my physician form assessing my own personal risk for
diabetes and CHD. Furthermore, I have been made aware that the information obtained
during this study may help Dr. Williams and his associates, learn how to better prevent
the increased risk for diabetes and CHD in postmenopausal women.
E. Confidentiality.
Any information obtained in connection with this study that can be identified with me
will be kept confidential to the extent permitted by law. A code number will be used to
identify any test results or other information I provide. Neither my name nor any
information from which I might be identified will be used in any data summaries or
publications.
F. Compensation for Injury
I understand that Oregon State University does not provide research subjects with
compensation or medical treatment in the event that I become injured as a result of
participation in this research project. However, if I sustain any injury during the data
collection, trained personnel will provide first aid.
G. Voluntary Participation Statement.
I understand that my participation in this study is completely voluntary and that I may
either refuse to participate or withdraw from the study at any time without penalty or loss
of benefits to which I am otherwise entitled.
H. Questions Regarding the Study
I understand that any questions I have about the research study or any specific procedures
should be directed to Daniel P. Williams, PhD at 737-5922..87
I.Undcrstanding and Consent.
My signature below indicates that I have read and that I understand the procedures
described above. I give my informed consent to participate in this study. I understand
that will receive a copy of this consent form.
Signature of subject
Name of Subject
Date Signed
Subject's Present Address
Subject's Phone Number
Signature of Principal Investigator
Date SignedAPPENDIX C
INSTiTUTiONAL RVEW BOARI) FOR tIPR0TECTtON OF HUMAN)IIJECJ'S
S
OREGON STATE UNJVERSflY
Report of Review
TO: Daniel Wflhiams, ExSS
RE: Hormones, physical activity, and coronary heart disease risk factors in
postmenopausai women
The referenced project was reviewed under the guidelines of Oregon State
University's Committee for the Protection of Human Subjects and the U. S. Department
of Health and Human Services. The committee has approved your application. The
informed consent form obtained from each subject should be retained in
programlproject's files for three years beyond the end date of the project.
Any proposed change to the protocol or informed consent form thetis not
included in the approved application must be submitted to the IRB for review and must
be approved by the committee before it can be implemented. The approval of this
application expires upon the completion of the project or one year from the approval
date, whichever is sooner.
Date:di/i /
Warren N. Suzuki,
Committee for the Protection of Human Subjects
(Education, 7-6393, suzukiwccmaiLorst.edu)APPENDIX D
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ID #
DATE
INITIALS
Pg. 1
Medical Questionniare
Medication Allergies- state reactions:
Cunent Medications - give dosage and include non-prescription drugs:
Previous Surgeries/Hospitalizations:
Medical Problems:
Accidents - specify type of injuxy incurred
Current Medical Concerns:
Primai Care Physician
Address
PhonePg. 2
Medical Questionnnaire
NoYes NoYes
RESPIRATORY (month. year) ENDOCRINOLOGY (month, year)
Have you ever had any of the followIng? (It so. Indicate when)
Asthma (wheezing)
Pneumonia
Severe brenchitis
Emphysema
Other lung trouble
Trouble breathing
Do you have chest pain?
Pleurisy
Tuberculosis skin test (state Pus or Hag)
Tuberculosis (infection or contact)
Chronic Bronchitis
Exposure to dangerous dust or fumes
Excessive snoring
Abnormal chest x-ray
Have you evercoughed up blood?
Do you often or regularty
Cough?
Raise sputum?
Do you often get chest colds?
When was your last chest x-ray
CIRCULATORY
Chest pain
High blood pressure
I
Have you ever taken heart or water pills?
Have you ever had a exercise stress test?
[ou ever had a coronary angegram?
[1ve you ever had any of the following? (It so. indicate when)
Hormone problems
Thyroid disease
Diabetes
DIGESTIVE
or
Trouble
or
I Has there been any change in your bowel
mOvflW1tS In the last 6 months?
you ever had any of the following? (If so, indicate when)
Hiatal or esophageal hernia
Duodenal or gastric ulcer
or
or
or
was your
an enema x-ray
occult cards
endoscopy (gas
had recent
90Pg. 3
Medical Questionnnaire
No Yes
JOINTS (month, year)
you, or do you
Or
CIJTANOUS
Have you ever had.
Sldn rashes
Scancer
Changesinamole
URINARY
Haveyouever had or been told you had
any of the following? indicate When)
KIdney disese or nephdtis
Protein or elbumininunne
Bloodorpuslnuflne
Urinary infection
Seaal tranernttted disease (STO)
How many lanes do you urinate:
at nIght
during the day
Doyouhave discomfort passing wine?
Haveyouever had a kidney s-lay (l.V.P.)?
OBSTETRICAL & GYNNECOLOGICAL
Have you ever had tumor(s), cyst(s), or
other breast disease?
Areyounow taldng hormones or birth
control p?
brand name and dose
Haveyouhad a partial or total hou?
Were your ovaries removed also
rightI left/both I dontimow
When was your last Pop smear
Do you examine your breaSts for lumps?
Are your menstrual periods normal?
At What age did your menstrual periods
begin?
At What age did menopause begin?
Areyousexually active?
HEMATOLGY & ONCOLOGY
Have you ever had
Anemia
Bleeding or bruising tendency
Cancer ortumor
X-ray or radiation treatment
i__Chemotherapy
NEUROLOGICAL
Have you ever had any of the following? (It so. indicate When)
Neurological disease
Frequent crtectxrent headaches
Loss of cofl$ciouaness
Convulsions or seicures
Severe head injury
Stioha
Paralysis or muscular wwaloress
Tremor or abnormal movements
Dlffictdiywithcoodnafton
Dsmcultylnwalring
Dilllcuftylnspealdng
Dertle vision orloss of vision
Nnam
Dlfflmdiywtm memory
SPEcIAL SENSES
Haveyouever had:
Glaucoma
Other major eye disease
Deafness
Alyromial noises in the ear
IMMUNIZATIONS
Date last Immunized (or:
Tetanus- diphtheria (every 5-10 years)
Pneumococcal Pneumonia
(Pneeumova
Influenza (annual- Fall)
9192
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Medical Questionunaire
HA8fl
PERSONAL HISS 3RY
What Is yow occupation? 0QuIt smoking In (fill orit below)
_____
year
usmoke______ packsadayfor years
MOOD
U Never drink alcohol
0 Quit drinking alcohol in________
FAMLY HEALTH
year
o alcoholic drinks per U day C week U month
it
oNever drink caflinated beverages
ODrink cupsof________aday
it cathnated beverage
Tyoe of Exercise and Frequency
Pluse the MowMg "um,etion abouP "re health of your,ediate fan*ç
RaATION Age Age at death Stateofhealth or cause of death
Mather.
Father
Brathers end sheets
Can
Have any otyouri'ncnedate famly or grandpwanls everhad any ofthe folowing? (if so. inctcale iialionshrp)
l4eaxt attack Seizures or epilepsy
Breast cancer Paridosons
Colon Alzhdanof a -___________
Other cancer (specify type)______________ Allergies
Highblood pressute Aicoflotism
Blood disease Psychiatric disease or suicide
Abnomhe bleeding _____ A disease which nars in the familyEndocrine and Metabolism Laboratory
Oregon State University
Department of Health and Human Performance
7-Day Physical Activity Recall
Day of the week form completed:
Acrostk rnornoD
Name_______________________
Birthdate _____________________
WeIght
Date________________________
1,Were you employed in the last 7 days (work & volunteering)? Yes ,No
2. How many total days of the last 7 did you work outside the home?Dno. of days (round to nearest day)
3. How many total hours did you work in the last seven days?0Dat work at home total hours
4.What days of the week do you consider to be your weekend or non-work days? For most people this would be Saturday and
and Sunday but it may be different for you.
0SundayEMondayDTuesday .EJWednesday ,DThursday .0FridayDSaturday
5.If you did not work your usual week, why did you work less than usual?
6.For the past seven days, and thinking only about activities that are at least of moderate intensity
how many days did you do activity or exercise that added up to at least 30 minutes each day? Elnumber of days (0 to 7)
7-day recall explain xqm.ncx cl day
xm . wike.lunch
pm. lunch-dlmner
ins. dlnner.alaep .. .., A-,.,'.... I 7One Week Ago Yesterday
t)wo1 pd&emr.r
Sleep 2)s.eww
W.pwe,kd
__________________________________ rp
3) d yoo d
Moderate ..
4) h*4y.
Othi
Hard
_____ _______________ _______________
C
VeryHard .'
Phyi3ciI Amty RcaII Pgt 2 of? Calculated Energy Expenditure kcal/kg/dayOne Week Ago Yesterday
I)wodpd&clnw
Sleep 2)i3upw.w,d
__________________________________________________________________________________________________________ np
) w&t d yco do
lsioos
Moderate
. .".."-..*. .....
s pm
4) hidy,
...........................
0
0
Hard
...,
'4
-
Very Hard
........ . ..
Phyictt ActMy ReaII - Pare 3 of 7 Calculated Energy Expenditure kcalfkgldayOne Week Ago
Yesterday
I) out p4 & uciunt
Steep
Wop wi.kd
top'
3) whit 44 7OU do
44 you o
work
hoinMld
totiuro
Moderate
______________________________________________________
put
0
4)m.
04w
Hard
Ui
VeryHard
tt'ticai ActMty Recall. Pae 4 oIl Cafculated Energy Expenditure_._ kcallkg/day
C'7. Was this a typical week in tenns of your usual pattern of activity or exercise?
ElYes
2El No Were you more or less active in the past week than you usually are? More ElLess
3-Month Physical Activity Recall
8.During your work week, on average how many hours per day do you spend sitting quietly? ElElaverage hours per day
(e.g., watching TV, working at a desk or computer, eating, or reading) (consider all waking time - before work and after)
During your weekend, on average how many hours per day. do you spend sitting quietly?El Elaverage hours per day
(e.g., watching TV, working at a desk or computer, eating, or reading) (consider aft waking time, before work and after)
9. How many flights of stairs do you climb up each day? (1 flight = 10 steps)El Elnumber of flights
10. 11 you had to add together the total minutes you spend walking during the day, how many minutes
would that be? Remember, add up your actual walking time and don't add in the time spent just standing.
Include your to and from walldng and any fitness walking. Don't try to remember every step, just give a
general idea of the time spent walking. 0 0 0total minutes per day
11. What is your usual pace of walking? Mark one only.
Casual or strolling (less than 2 miles per hour)
1El Average or normal (2 to 3 miles per hour)
0Fairly brisk (3 to 4 miles per hour)
0Brisk or striding (4 miles per hour or faster)
12, Do you regularly do strength and flexibility exercises like sit-ups, push-ups, yoga, or stretching?
ElYesHow many days per week do you do these exercises?0number of days (0-7)El El Eltotal minutes ea session
2El No
I'hykaI Acvvey R1c2fl - PagiS of 7
'-4$2 Months Physical Activity Recall
1.Thinking about the things you usually did at work during the last 12 months, how would you describe the kind of physical activity
you performed?
Inactive Light Moderate Heavy Not applicable
2.Thinking about the things you usually did in your home during the last 12 months, how would you describe the kind of physical
activity you performed?
Inactive Light Moderate Heavy
3.Thinldng about the things you usually did in your leisure time during the last 12 months, how would you describe the kind of
physical activity you performed?
Inactive Light Moderate Heavy
Inactive Light Moderate Heavy
sitting teaching mail carrier regular vigorous activity
standing quietly light gardening construction
light regular household carrying heavy boxes
deskwork brisk walking strenuous farm work
walkIng >1 0mm recreational tennis strenuous gardening
reading leisure bicycle ride swimming
watching TV fishing moderate housework ioggIng
quiet pursuits bowling moderate gardening singles tennis
golf high-intensity aerobics
PhyIcActivity Recaigt 6 oilInterviewer Evaluation
1. Were there any problems with this survey?
Yes No Explain
2. Do you think this was a valid interview?
Yes No Explain
3. List any activities reported by participant which you don't know how to classify
FORM completed by Onidak) a bas.lin. PliysIal Activity Recall. Page loll